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Background: Malaria is still the number one killer in sub-Saharan Africa, even though it is in principle 
a preventable and treatable disease. A large amount of progress has been made over the last 
decades, but there is still a long way to go. We wanted to look at some of the challenges facing one 
sub-Saharan country, Malawi, with a focus on how international and national guidelines help this 
country with the burden of this disease. We also wanted to look at how research may change these 
guidelines in the future, and assess if there is a role for using DDT as a means for controlling malaria.  
Method: This study is largely based on literary sources, in addition to a personal excursion to Malawi 
in order to gain first-hand knowledge and a better understanding of the challenges facing the 
country.  
Discussion and conclusion: We found that the current international guidelines are effective tools in 
the fight against malaria, and that DDT use is still indicated because of a lack of better alternatives. 
Through developing these recommendations and helping in their fulfilment, international 
organizations such as WHO play an important role in the continued fight against malaria. Countries 
can use the international recommendations to develop their own national guidelines, adapting them 
to better suit local resources and priorities. On-going research has a lot of potential to help make the 
guidelines become even more effective in the future. Progress in countries such as Malawi is being 
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Malaria is still the biggest killer in sub-Saharan Africa, despite continued efforts to contain and 
counteract the disease. In Malawi, malaria accounts for 40% of hospitalizations of children under five 
and 40% of overall hospital deaths (1), even though malaria can be prevented and treated effectively 
given the right resources (2). 
The World Health Organization (WHO) has developed international guidelines that hope to help in 
the fight against malaria, with a focus on preventing, treating and overall reducing the burden of 
malaria in the world (3). Malawi has implemented most of these guidelines in their own set of 
national guidelines (1).  
In addition, a number of studies and projects are underway, looking at both preventive and 
therapeutic problems, hoping to find ways to make the fight against malaria more efficient.  
Additionally, the use of DDT has been surrounded by controversy over the last decades. It went from 
being one of the most effective tools in the control of mosquitoes to being effectively banned by the 
Stockholm convention in 2001, due to environmental considerations and concerns about health and 
safety (4). 
We want to assess what kinds of challenges Malawi is facing concerning malaria, and to look at how 
the international and national guidelines address these challenges. Further, we want to look at how 
research can affect these guidelines in the future, and finally evaluate if there still is a role for DDT in 
the prevention of malaria. 
This paper is largely based on literary sources, mainly books, guidelines and scientific studies, in 
addition to the first-hand knowledge acquired in Malawi. During our trip to Malawi, we visited the 
Zomba Central Hospital, where we were in contact with several different on-going research projects. 
We hope to be able to use this experience to gain a better understanding of how the health care 
system in Malawi works, and how Malawi attempts to solve the challenges they face when it comes 
to malaria. 
We will start by describing the parasite and the disease it causes, looking at how malaria can be 
diagnosed and treated, followed by a presentation of the different preventive methods and a more 
in depth review of DDT and its role in fighting malaria.  
Thereafter, the aspect of malaria globally will be presented, along with the international guidelines 
for interventions addressing the problem. Further, an introduction of Malawi and the impact of 
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malaria there will follow, in addition to a description of the research projects we are connected to 
locally.  
This will be followed by a discussion of the challenges facing Malawi regarding health care system, 
implementation of guidelines and adherence to them. Finally, we will discuss how research may 
affect the current situation through changing guidelines, as well as whether there is a role for 
utilization of DDT. 
This paper would not be possible without the helpful assistance of our supervisors, Dr Jon Øyvind 
Odland from Universitetet i Tromsø and Dr Kamija Phiri from the University of Malawi. We want to 
thank them for all their support, both in Norway and in Malawi. In addition, we would like to express 
our sincere gratitude to Dr Andrew Matchado and the rest of the staff at Zomba Central Hospital for 




This paper is largely a literary review based on external sources in addition to first-hand experience. 
The studies used in this paper were collected through semi-systematic searches on PubMed 
conducted between November 2012 and May 2013. The studies were selected by title, abstract and 
contents, with a special focus on studies relevant to sub-Saharan Africa. In addition to the scientific 
studies, we used additional information on various websites that we deemed trustworthy, as well as 
in books. The information on the WHO guidelines is mainly based on their publications.  
In addition to the literature, we wanted to visit Malawi ourselves to gain first-hand knowledge that 
we could use to substantiate the information and discussion in this paper. Two of the authors of this 
paper went to Malawi on the 16th of March, and returned to Norway 20th April. During this trip, we 
actively reached out to the public health care system in Malawi; we spent a week in Zomba, talking 
to public health researchers and doctors in Zomba Central Hospital, in addition to coming in contact 
with other health personnel in Malawi, both local and foreign. The trip to Malawi was entirely self-
funded by the authors. 
In addition to literary sources we found ourselves, our contact person and supervisor in Malawi, Dr 
Kamija Phiri, supplied us with additional documents, among them the treatment and prevention 





We will start by presenting the information we feel is needed to discuss this thesis, divided into nine 
chapters. First, we will present malaria itself, including how the clinical manifestations are affected 
by factors such as age, immunity, pregnancy and HIV; afterwards, two chapters will describe how it is 
diagnosed and treated. The fourth chapter concerns prevention, wherein different measures that can 
prevent malaria are presented. Because of its importance to the subject of this thesis, DDT is 
described by itself in the fifth chapter. After this, we will present the global aspects of malaria, 
followed by a presentation of WHO, and then of the WHO guidelines that apply to malaria endemic 
countries. Finally, we will present Malawi, with a special focus on the challenges they face when it 
comes to health care and malaria in particular; in this chapter, we will also give a short summary of 
the different studies we were connected to during our visit to Malawi. 
5.1 Malaria 
We will begin by introducing malaria, starting with a short description of the traits of the Plasmodium 
species. This will be followed by the pathophysiology and clinical presentation of the disease, 
succeeded by how this depends on immunity, age, pregnancy and the presence of HIV-infection. 
Malaria is a protozoal infection (5), which can be caused by several Plasmodium species: P. 
falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi (6). Malaria is most commonly transmitted 
through female mosquitoes of the Anopheles genus, but can also be transmitted congenitally or 
through contaminated blood, for example via blood transfusion or used needles (7). 
When malaria is transmitted through mosquito bites, Plasmodium parasites in the form of 
sporozoites are transferred from the mosquito’s salivary glands into the person’s bloodstream. The 
parasites are incorporated by hepatocytes in the liver, where a maturation process results in 
schizonts. When the hepatocyte ruptures, the schizont divides into thousands of merozoites (7). 
These merozoites invade erythrocytes, where they mature into either trophozoites or gametocytes. 
The trophozoites of the different species can be differentiated using microscopic examination (8). 
The trophozoites then develop into schizonts, which later rupture and result in more merozoites that 
can invade new erythrocytes, thus repeating the cycle. Gametocytes stay inside the erythrocytes 
until they are taken up by a mosquito, which is then re-infected; the life-cycle is complete, with new 
sporozoites stored inside the mosquito’s salivary glands. In addition to the stages described above, P. 
vivax and P. ovale have dormant stages, hypnocytes, which remain in the liver (7). 
The Plasmodium life cycle is reliant on the Anopheles mosquito as a vector and an adequate 
temperature. Therefore, the geographical distribution of malaria is determined by the distribution of 
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the Anopheles mosquitoes, as well as areas having the correct climate. The transmission has 
traditionally remained at altitudes below 2000 m (5). However, in recent years there has been 
increased malarial transmission in areas of higher altitudes in Africa, which may be a result of climate 
change resulting in increased temperatures in high-altitude areas (9).  
According to the World Health Organization (WHO), malaria transmission intensity can be divided in 
four different categories: holoendemic, hyperendemic, mesoendemic and hypoendemic. 
Holoendemic includes areas with perennial transmission of high intensity, where the prevalence of 
parasitaemia among infants is above 75%. Hyperendemic includes areas with seasonal transmission 
of high intensity, defined as prevalence of parasitaemia above 50% in children between 2–9 years of 
age. Mesoendemic includes areas with intermediate transmission, defined as prevalence of 
parasitaemia in 11–50% of children between 2–9 years of age. Finally, hypoendemic includes areas 
where malaria transmission is low, defined as prevalence of parasitaemia below 10% in children 
between 2–9 years of age (10). The level of transmission intensity can be simplified further into high, 
moderate and low transmission areas. High transmission areas include holoendemic and 
hyperendemic areas, while moderate corresponds to mesoendemic area and low to hypoendemic 
area (11). 
5.1.1 Pathophysiology 
When malaria infected erythrocytes rupture, merozoites and digestive vacuoles are released. These 
vacuoles contain haemozoin, a pigment by-product of haemoglobin digestion; this pigment activates 
both the complement system and the coagulation system, which turns the focus of the immune 
system away from the merozoites. The immune response induces cytokine release leading to 
phagocytation of vacuoles (12), and can result in splenomegaly (8). Each erythrocyte cycle lasts about 
48 hours in P. vivax, P. ovale and P. falciparum, and 72 hours in P. malariae (5). P. knowlesi has an 
erythrocyte cycle of about 24 hours (13).  
The malaria-infected erythrocytes by P. falciparum have changed cell surfaces, which affects the 
interaction with endothelial cells by making the infected erythrocytes adhere to the vessel walls (8).  
Research has shown that the Plasmodium species reduces human immune response towards itself, 
and through this down-modulation impairs the development of immunity against malaria. The 
acquired immunity protects only against clinical malaria, allowing asymptomatic parasitaemia. Even 
this degree of immunity takes years to develop, and requires frequent re-infection over a long time 
period (14). As the immunity depends on exposure, the degree of protection is affected by the 
transmission intensity in the area. A correlation between the median parasite density in febrile 
patients and transmission intensity has been seen. While 95% of febrile patients with P. falciparum 
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had over 200 parasites per microlitre blood in a high transmission setting, the same number for 
settings with lower transmission was 90–95%. P. vivax tends to have higher parasite densities than P. 
falciparum (11). The clinical impact of development of immunity will mentioned later. 
5.1.2 Clinical manifestation of malaria 
The classic symptom of malaria is high fever spikes every third or fourth day, depending on the 
Plasmodium species (5). This classic fluctuation is caused by the erythrocyte cycle (8), but this pattern 
is not always distinctive. The fluctuations are less marked with falciparum malaria, and the 
temperature changes can be more irregular with all species during the first days of illness (5). 
Common symptoms in addition to fever include vomiting and headache (5). The clinical 
manifestation is rarely distinctive (15), and even fever is not always consistent. The lack of fever is 
not necessarily a sign of mild disease. For instance, in one African trial, children between 8 months 
and 4 years of age without fever or a history of fever had a higher mortality rate than the febrile 
children among admitted children with confirmed malaria (16). 
Muhe et al. observed that splenomegaly, pallor and history of chills were statistically increased in 
patients with parasitaemia. They further theorized that detection of splenomegaly and pallor could 
increase the probability of making the correct diagnosis when used by health workers when other 
diagnostic possibilities are unavailable (17). In Tanzania, a trial based on children admitted with 
malaria infection found pallor in 59% and splenomegaly in 56% of children between 1 and 7 months 
of age. The association was weaker in older children, where the signs were present in only 31% and 
39%, respectively (16).  
In their review over symptoms and signs connected to malaria, Chandramohan et al. found that the 
clinical aspect alone was not sufficient to separate malaria from other febrile illnesses. They also 
found that predictors associated with malaria differed between locations (18). 
5.1.3 Severe malaria and complications after infection 
Roca-Feltrer et al. estimated the incidence of severe malaria to be 5.7/1000 per year among children 
below five years of age in malaria endemic areas (19). Patients with severe falciparum infections 
often have high parasite counts, and may develop severe symptoms from several organ systems (15). 
The severity of the disease may increase in a short time-span, especially in children where the 
situation can deteriorate within hours (5). Schellenberg et al. found that among malarial admissions, 
half of the mortality cases died within the first 24 hours (16).  
A multicenter study from WHO have measured the prevalence of different clinical features in 
children with severe falciparum malaria. They found that 54.1% had severe anaemia, 17.7% had 
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cerebral malaria and 13.2% hypoglycaemia, while jaundice and respiratory distress were present in 
less than 2% (20). Kidney failure, metabolic acidosis and high lactate levels have also been associated 
with severe malaria (6).  
Cerebral malaria is a clinical syndrome where the patient has reduced consciousness that can 
develop into coma or death (5). Clinical manifestations connected to impaired consciousness include 
convulsions, reduced response to painful stimuli, abnormal motor posturing and increased 
intracranial pressure (13).  
Among the children with known outcome 14 days after they were admitted for severe falciparum 
malaria, almost 10% had died and 1.7% had neurological sequelae. Most of the children made a full 
recovery. In that study, the case-fatality rate of cerebral malaria was estimated at 17.7% (20). 
Epilepsy may also be a late sequela to cerebral malaria, which can appear months after the illness 
itself. It has been estimated that as many as 10% of children with cerebral malaria may go on to 
develop epilepsy (13). 
Severe anaemia has been associated with malaria infection (21). Malaria infection cause anaemia 
through destruction of infected and uninfected erythrocytes, insufficient erythropoiesis, folate 
depletion and reduced proportion of red blood cells in the circulation, through sequestration and 
splenomegaly (5). Perkins et al. claims that the most important cause of severe anaemia with P. 
falciparum is suppression of the erythropoiesis (6). The anaemia may develop rapidly or be of a more 
chronic character (13), the latter caused by persistent infections (22). 
Hansbroek et al. observed reduced erythrocyte production in almost half of the children with severe 
anaemia. A fifth of these had another mechanism causing anaemia in addition to the reduced 
erythrocyte production. For those who tested positive for malaria, the proportion with failure to 
produce erythrocytes was 42.1%. In this study, they also found that to reverse the production deficit, 
all the aetiological components should be addressed (23), which may include bacteraemia, 
hookworm infection, HIV infection or vitamin deficiency (21).  
Schellenberg et al. found that hypoglycaemia was an independent risk factor for mortality among 
children admitted to the hospital because of malaria (16). Hypoglycaemia has also been estimated to 
double the mortality in children when accompanying cerebral malaria or severe anaemia (20).  
Even though P. falciparum is responsible for most of mortality from severe malaria, other species 
may progress in severity as well. There are many similarities between severe infections caused by P. 
falciparum and P. vivax, though the latter is less common (13). Vivax malaria often includes 
respiratory symptoms, and patients with severe disease may develop acute respiratory distress 
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syndrome (ARDS). Increased alveolar permeability through cytokine release is believed to be the 
mechanism for this. Severe vivax malaria may also progress to coma, though this is rare. As the 
mechanism for falciparum malaria is connected to its sequestration, the mechanisms for vivax-
induced coma are more uncertain. Vivax malaria resulting in renal failure has also been described 
(24). As P. vivax has hypnozoites, relapse of infection is common. These relapses make the chronic 
complications to malaria infections, such as anaemia, more severe (24). Severe malaria caused by P. 
knowlesi is similar to severe falciparum malaria, but without affecting consciousness (13).  
5.1.4 Age and its effect on malaria 
Age has an effect on the clinical manifestation of malaria, both directly and through the development 
of immunity. Immunity will, as described earlier, allow asymptomatic parasitaemia instead of clinical 
disease. As immunity develops, symptoms of malaria and severity of the disease will thereby subside 
(25).  
There have been several reports on the effect of transmission intensity on the age distribution of 
clinical disease. Okiro et al. found that the proportion of infants among malarial admissions had a 
strong positive correlation with the transmission intensity in the area (25). Schellenberg et al. 
observed that 54% of the malaria mortality among hospitalized children in a highly endemic area was 
in children below one year of age (16). 
Carneiro et al. found that a bisection of the median age for malaria mortality between seasonal 
moderate endemic areas and perennial highly endemic areas, at 28 and 12 months of age 
respectively, could be attributed to increased immunity in the high transmission areas. The same 
tendency is seen in median ages of clinical malaria, at 32 months in areas of perennial high 
transmission, compared to 72 months in areas with moderate transmission (26). 
Even though the reductions described above show a tendency for transmission dependency, the 
median ages outside high transmission areas were still low. The median age of 28 months for malaria 
mortality, demonstrates age dependence regardless of transmission intensity (26).  
Snow et al. found that the relative frequency of cerebral malaria was significantly higher in low-to-
moderate transmission areas than in high transmission areas (27). Aponte et al. suggest that this 
difference may be partly caused by the difficulties in evaluate neurological status during infancy (28). 
In addition to the difference in mortality rates, the course of the disease may differ according to age. 
While children often have anaemia and hypoglycaemia as complications to their malaria infection, 




Because of the high proportion of malaria illness in childhood, communities with high non-seasonal 
transmission may consider malaria as a children’s disease. The developed immunity against malaria is 
dependent on constant exposure, as mentioned earlier. Changes in transmission status and 
increasing prevention may therefore expand the age group at risk for symptomatic infection (15) as 
their asymptomatic parasite density levels decreases (29). 
5.1.5 Malaria in pregnancy 
Pregnant women are more susceptible to malaria infections. They have higher parasite counts than 
other adults, with the highest density between 9 and 16 weeks of gestation (30). They are also more 
likely to have symptomatic disease (31). 
There are three specific changes in the placenta due to P. falciparum: first, accumulation of infected 
erythrocytes in the intervillous spaces; second, fibrin deposit containing malaria pigment, 
haemozoin; and third, intravillous infiltrates of macrophages and monocytes containing haemozoin. 
A high density of erythrocytes in the intervillous space is associated with preterm delivery. 
Intravillous infiltrates of haemozoin-containing leukocytes is associated with low birth weight (LBW) 
and maternal anaemia, and is more common in primigravidae. These three changes can be found on 
histopathological examination of placental tissue up to one month after infection. P. vivax does not 
change morphology in the placenta (30), but it is still associated with maternal anaemia and LBW 
(32). 
Pregnant women in non-endemic areas often have severe disease (30), which increase the risk of 
stillbirths, spontaneous abortions and maternal death (31). In endemic areas, pregnant women may 
have few symptoms or be asymptomatic due to acquired immunity (31). However, the infection 
often leads to severe anaemia (33). The severity of maternal malaria infection decreases with parity 
in endemic areas, but this seems dependent on stable malaria transmission (30). 
Guyatt and Snow estimated in 2001 the median proportion of placental infection to be 0.254 in all-
parity pregnant women from endemic areas of P. falciparum (34). Two other reviews found similar 
prevalence numbers (32). Using 0.254 as prevalence for malaria in pregnancy, Guyatt and Snow 
estimated that malaria could be the cause of 11.4% of the neonatal mortality and 5.7% of the infant 
mortality in endemic areas (34). 
Trials have assessed the link between maternal malaria infection during pregnancy and LBW of the 
new born. Guyatt and Snow found the proportion of LBW to be 0.230 in babies where placental 
infection was found, compared to a 0.110 where infection were not found. They also found 
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significant difference in median average birth weight (34). A study in Côte d’Ivoire found similar 
results, with LBW in 22.2% in cases with placental infection and 10.1% in cases without (35). 
In sub-Saharan Africa, babies with LBW have three times higher infant mortality rate than babies 
with normal birth weight (34, 36). A different study estimated the neonatal mortality at 0.152 among 
LBW babies, compared to 0.017 among babies with normal birth weight (34).  
In addition to the effects described above, maternal malaria infection reduces the transport of 
antibodies over the placenta. LBW and prematurity is also associated with lower levels of antibodies 
in cord blood. This may leave the neonate at higher risk for infections and therefore increase 
neonatal mortality and morbidity further (33). 
5.1.6 Malaria and HIV 
There is much overlap between the epidemiological areas of malaria and HIV. In sub-Saharan Africa, 
several countries where a majority of the population is exposed to malaria also have HIV prevalence 
above 10% in the population between 15–49 years of age (37). 
In addition to the ones giving fever in the general population, several other microbes can cause 
febrile illness in people living with HIV infection. As a result, people with HIV infection have increased 
probability of a febrile illness with a different aetiology than malaria (37).  
In areas where the adult population normally have acquired immunity against malaria, HIV-infected 
adults have increased risk of clinical malaria. This increase correlates with the degree of 
immunosuppression (38). In areas where the transmission is insufficient to develop immunity, HIV-
infected have an increased risk of developing severe malaria (39). Higher treatment failure rates 
among HIV-infected adults has also been reported (37). 
Malaria transmission rates affect the impact of HIV on malaria in children as well. In stable areas, HIV 
infection is associated with higher occurrence of clinical malaria. There has been seen a correlation 
between degree of immunosuppression and parasite densities here as well. In areas with unstable 
transmission, HIV infection is associated with increased risk of severe malaria (37).  
Severe anaemia has been associated with malaria infection (21). HIV can transmit through 
contaminated blood, and WHO notes that thousands of African children have become HIV positive 
after receiving blood transfusion for their severe malarial anaemia (37).  
As mentioned earlier, malarial infection during pregnancy increases the risk of maternal anaemia, 
LBW, stillbirth and spontaneous abortion. Both pregnancy and HIV reduce the ability to contain 
malaria parasitaemia. Pregnant women with HIV infection therefore have increased risk of high levels 
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of parasitaemia and have increased risk of developing symptomatic disease (40). They also have 
increased risk of maternal anaemia, prematurity and LBW (37). Normally, the reduction in immunity 
during pregnancy decreases with increased parity in areas of stable transmission. The largest 
differences attributed to HIV infection are therefore seen in multigravida women (37). 
5.2 Diagnostics 
As described above, clinical presentation of malaria may vary, and symptoms are generally 
unspecific. Additional diagnostic measures are therefore needed to verify the diagnosis. Several 
different diagnostic techniques are available, of which microscopic diagnosis and rapid diagnostic 
tests are the most commonly used today. Other possibilities include polymerase chain reaction (PCR), 
fluorochrome microscopic techniques and serological procedures (41).  
A description of the most common techniques, as well as special considerations regarding diagnostics 
of placental malaria, will follow below. 
5.2.1 Peripheral blood film microscopy 
A thick and thin blood film is used when using a 
microscope to diagnosing malaria infection. The thick 
blood film is more sensitive for parasites, especially at 
low densities. The samples are stained, often using the 
Giemsa, Wright’s or Field’s staining techniques. 
Parasitaemia at 50 parasites/microlitre blood can be 
found if someone with experience performs the 
examination. Differentiating the Plasmodium species is 
easiest in thin blood films (42). 
Parasite count (parasites/microlitre) can be found by counting parasites in proportion to either white 
or red blood cells, depending on the type of blood film used, and estimating the parasite count 
through the numbers of cells per microlitre (42). 
5.2.2 Rapid diagnostic tests 
Immunochromatographic tests uses antibodies against malaria antigens, with mechanisms displaying 
positive test as change of colour. There are several options available as dipstick kits, using different 
kinds of antigens such as HRP-II, pLDH or aldolase. Some of these, for example HRP-II-based tests, are 
selective for P. falciparum, while others can be used for all species (42). 
  
Figure 1: Blood slides used to diagnose 
malaria using a microscope. Zomba Central 
Hospital, Malawi; picture taken by authors. 
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Several HRP-II-based RDTs have been tested with 
sensitivities above 75% and specificities above 
80%, when parasite density was above a hundred 
parasites per micro litre. A review by Abba et al. 
found that these RDTs had sensitivity of 95.0% and 
specificity of 95.2% (43). pLDH-based RDTs have 
been tested with sensitivity and specificity for P. 
falciparum at 94% and 100%, and for P. vivax at 
88% and 99%, respectively. This kind contains 
several antibodies, of which one is falciparum 
specific. Abba et al. found the sensitivity and specificity for pLDH-based test to be 93.2% and 98.5, 
respectively (43). RDTs based on aldolase have been more dependent on higher parasite densities. 
These can detect all Plasmodium species (42). 
5.2.3 Other diagnostic methods 
PCR-based methods have high sensitivity and specificity, with good ability to make the diagnosis even 
with low parasite densities (44). This method is demanding in regard of equipment and staff, which 
limits its use (45). Fluorochrome microscopic techniques may give a sensitive result if the technician 
has experience; however, it is costly, needs special equipment and is unable to differentiate between 
the Plasmodium species (42). Serology may give useful for information on antibody response for 
epidemiological purposes (44). 
5.2.4 Diagnosing malaria in pregnancy 
Diagnosing malaria during pregnancy differs from diagnosing the non-pregnant. The gold standard 
for diagnosing placental malaria infection is not peripheral blood microscopy, but histological 
examination of the placenta itself. Another highly specific diagnostic possibility is placental blood 
microscopy. Neither of these can be done routinely before delivery (45). 
Options for detecting placental infecting during pregnancy therefore rely on tests from peripheral 
blood. Kattenberg et al. compared PCR, RDT and peripheral blood microscopy with placental blood 
microscopy and found that PCR was the most sensitive option, with sensitivity at 94%, while 
peripheral blood microscopy was the most specific, at 98%. The RDTs was mid-range on both, with 
sensitivity and specificity at 81% and 94%, respectively. Peripheral microscopy detected only 72% 
(45). 
Figure 2: An example of an HRP-II RDT used in 
Malawi. Picture taken by authors. 
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5.3 Antimalarial medications 
In this chapter, we will take a closer look at the different antimalarial treatment options available 
today, with a special focus on the drugs currently recommended by WHO in their treatment 
guidelines. 
Many different drugs spanning several chemical families are in use today for treatment of malaria 
(see Table 1 below) (46). The optimal therapeutic choice depends on several factors, including the 
Plasmodium species, the drug resistance in the area, as well as the efficacy, the availability, cost and 
side effects of the medication, and more (2). 
 
The therapeutic treatment of malaria has a long history spanning several continents. In China, the 
qinghao plant, which we now know contains the antimalarial drug artemisinin, has been used in the 
treatment of intermittent fevers since at least the 4th Century A.D. In Western medicine, the 
cinchona tree, native to South America, was the basis for antimalarial treatments; cinchona bark 
infusions containing quinine has been used against malaria since at least the late 1600s, infamously 
giving rise to tonic water. Artemisinin and quinine remains cornerstone drugs in the medical 
treatment of malaria to this day (47). 
During the latter half of the 20th Century, the efficacy of the most widely used antimalarial agents, 
most notably chloroquine and amodiaquine, dropped significantly because of increasing parasite 
resistance, with devastating public health consequences (47). 
Facing the rising drug resistance, the recommended first-line treatment for uncomplicated P. 
falciparum malaria has been artemisinin-based combination therapies (ACTs) since WHO updated its 
Table 1: Antimalarial drugs currently in use today (46). 
Chemical family Drugs 
4-Aminoquinolines Chloroquine, amodiaquine, piperaquine 
Amino-alcohols Quinine, quinidine, mefloquine, halofantrine, lumefantrine 
Sulphonamides/sulphones Sulfadoxine, sulfalene, dapsone 
Biguanides Proguanil, chlorproguanil 
Diaminopyrimidine Pyrimethamine 
8-Aminoquinoline Primaquine 
Sesquiterpene lactones Artemisinin, arteether, artemether, artesunate, dihydroartemisin 
Naphtoquinone Atovaquone 
Antibiotics Azithromycin, clindamycin, doxycycline, tetracycline 
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treatment recommendations in 2001. Today, most malaria-endemic countries use ACTs as their first-
line treatment for malaria caused by P. falciparum, although other drugs are still used for special 
patient populations (2). 
5.3.1 Quinine and other amino-alcohols 
Quinine is an aryl amino-alcohol that has been used to treat malaria in the Western world since the 
early 1600s. It is a naturally occurring compound found in the bark of the cinchona tree (Cinchona 
officinalis) native to South America (48, 49). Several other closely related compounds exist in the 
cinchona bark, including quinidine, cinchonine and cinchonidine, all with approximately equally 
potent antimalarial properties (48).  
Even though the drug has been used extensively over the last centuries, it remains a viable treatment 
option to this day, especially for vulnerable patient groups such as pregnant women or children, and 
when used in combination with other drugs (48). 
Quinine has a small therapeutic window, and the collection of the benign, but unpleasant, side 
effects often seen at therapeutic concentrations is called cinchonism, and include nausea, headache, 
tinnitus, hearing impairment and blurred vision. More severe side effects, such as vomiting and 
vertigo, may also occur. The small therapeutic window is one of the largest challenges when it comes 
to modern usage of quinine, as the frequent side effects often leads to poor compliance and may 
contribute to early treatment termination (49). 
Despite being one of the oldest drugs used in antimalarial therapy, the antimalarial mechanisms are 
still not fully understood (48), but it has been theorized that it inhibits the detoxification of haeme, 
similarly to the 4-aminoquinolones (2).  
Other than quinine, which remains as one of the drugs recommended in the treatment of 
complicated P. falciparum malaria, there are also several quinine derivatives in use today (2). The 
most widely used among these is lumefantrine and mefloquine. 
Lumefantrine is currently used as a partner drug in the ACT artemether-lumefantrine. It is a generally 
well-tolerated drugs with few reported side effects and a relatively short terminal elimination half-
life of 3 days. However, bioavailability is highly dependent on administration with fatty foods; the 
absorption of the drug doubles after a meal (2). 
Mefloquine is used in combination with artesunate as an ACT (46); however, it is also among the 
most widely used antimalarial drugs used for chemoprophylaxis by foreign travellers going to malaria 
endemic countries. Mefloquine has a half-life of around 21 days. Mefloquine has several side effects, 
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including rather infamous psychiatric side effects such as sleep disturbances, dysphoria and 
abnormal dreams. In addition, more serious neuropsychiatric disturbances, such as seizures, 
encephalopathy and psychosis, have been known to occur. This is especially true when mefloquine is 
used to treat severe malaria, where the incidence of such disturbances may be as high as 5% (2). 
5.3.2 Chloroquine and other 4-aminoquinolines 
The 4-aminoquinolines, most notably chloroquine, amodiaquine and piperaquine, have been widely 
used in the treatment of malaria since after the World War II (47). These drugs work by inhibiting the 
detoxification of haeme, which is a by-product of haemoglobin digestion; by inhibiting this process, 
toxic haeme gradually builds up inside the food vacuoles of the parasite, and eventually kills the 
parasite (50).  
The 4-aminoquinolones and their metabolites have very long half-lives; for chloroquine, the 
estimated terminal elimination half-life is 1–2 months. The half-life of the active metabolite of 
amodiaquine has been estimated to be between 9 and 30 days (51), while piperaquine has a half-life 
of approximately 20–22 days (52). These long half-lives are partly beneficial, as they will probably 
infer an added prophylactic effect post-treatment; however, as will be described later, the longer 
half-lives of these compounds might also lead to increased resistance (52). 
Amodiaquine has a significant risk (between 1 in 1000 and 1 in 5000) of serious and potentially fatal 
adverse reactions, including neutropenia, agranulocytosis and hepatitis, when used prophylactically. 
Prophylactic use is therefore no longer recommended. The frequency of serious adverse reactions 
when used as treatment for malaria is unknown, but studies indicate that the benefits of using 
amodiaquine in treatment outweigh the risk of serious adverse effects (2, 51). 
Extensive resistance over the last decades has rendered chloroquine almost useless for treating P. 
falciparum malaria in most malaria-endemic areas. Recent research has tried to assess if chloroquine 
has a role in the use for intermittent preventive treatment of malaria in pregnancy in combination 
with azithromycin, and the results are promising (36). Amodiaquine and piperaquine are still used as 
partner drugs in ACTs in areas where the efficacy of these drugs remains high (46, 47).  
5.3.3 Pyrimethamine and sulfadoxine 
Following the emergence of chloroquine resistant malaria, many countries switched to sulfadoxine–
pyrimethamine (SP) as their first line treatment for malaria. Even though pyrimethamine and 
sulfadoxine are two separate drugs, they both target the same biosynthesis pathway and the 
combination of these drugs is therefore regarded as a monotherapy (46). 
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SP works by suppressing the folate synthesis pathway in the parasites, thereby inhibiting growth (50); 
as such, these drugs are relatively slow-acting schizontocides. The half-lives of both drugs are around 
4 days. As with other sulphonamide drugs, sulfadoxine may induce severe and potentially fatal 
allergic reactions, including toxic epidermal necrolysis and Steven–Johnson syndrome. In comparison 
with other sulphonamide drugs, the relatively long half-life of sulfadoxine may cause the allergic 
reactions to be more severe (2). 
The most common formulations contain 20 parts of sulfadoxine with 1 part pyrimethamine, 
commonly in 500 mg sulfadoxine and 25 mg pyrimethamine formulation (Fansidar®) (2). Even though 
widespread resistance has rendered SP almost useless in large parts of the malaria endemic world, it 
is still frequently used as intermittent preventive treatment for pregnant women, as both drugs are 
regarded as safe to use in pregnancy. In addition, SP has found use in combination with an 
artemisinin derivative as an ACT in the parts of the world where resistance to SP has not yet 
developed extensively (46). 
5.3.4 Antibiotics 
Several antibiotics also have antimalarial properties, and antibiotics used in malaria treatment 
include tetracyclines (especially doxycycline) and clindamycin. The use of antibiotics in the treatment 
of malaria is no longer generally recommended where good alternatives exists (2), but they still have 
a place in specific patient populations, including pregnant women and use as prophylaxis for 
travellers, as well as in combination with other drugs (2, 53). Azithromycin is another antibiotic with 
antimalarial activity, though it is currently mainly used in intermittent preventive treatment in 
pregnancy (36). 
5.3.5 Artemisinin and its derivatives 
Artemisinin, also called qinghaosu, is another naturally occurring substance used for treating malaria 
for centuries (47). Artemisinin is a sesquiterpene lactone that was isolated and extracted from the 
leaves of Artemesia annua, or sweet wormwood, in China in the 1970s. It quickly became a focus of 
attention for its potential use in treating malaria (54). 
The parent drug, artemisinin, has now largely been replaced with the more potent synthetic 
derivatives. The main derivatives in use today are artemether, artesunate and dihydroartemisinin. 
Dihydroartemisinin is the main active metabolite for the synthetic derivatives of artemisinin, but it 
can also be given as a drug in its own right (2, 55).  
Artemisinin is a very rapidly acting drug with an elimination half-life of approximately 1 hour. The 
peak plasma concentrations occur 3 hours after administration. Artemisinin and its derivatives work 
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by inhibiting PfATPase, which is an essential calcium adesonine triphosphatase. They have a very 
broad activity against malaria parasites, killing both asexual parasites and gametocytes in P. 
falciparum (2). 
In order to prevent the development of resistance, artemisinin and its derivatives should be used in 
combination with other drugs, so-called ACTs. ACTs now constitute the basis for first-line treatment 
against malaria in essentially all malaria endemic countries (2, 46). In addition to preventing the 
development of resistance, ACTs have a far higher treatment efficacy than using artemisinin-based 
monotherapy (55). 
5.3.6 Artemisinin-based combination therapies 
The emergence of resistance to commonly used antimalarial drugs, mainly 4-aminoquinolones (e.g. 
chloroquine) and sulphonamides (sulfadoxine), has been a major obstacle in the fight against malaria 
for several decades, and has necessitated a change in the recommended treatment guidelines in 
areas with endemic malaria. Modern malaria treatment guidelines are largely based on ACTs instead 
of monotherapy (46). 
As the name implies, ACTs use artemisinin or one of its derivatives paired with a partner drug with a 
different pharmacological mode of action. Having two distinct modes of action slows down 
development of resistance for both the artemisinin derivative, as well as increasing the efficacy of 
the treatment itself (46). 
WHO currently recommends five different ACTs, all of which are in use, either as first-line or second-
line treatment, around the world. These five drugs are artemether–lumefantrine, artesunate–
amodiaquine, artesunate–mefloquine, artesunate–sulfadoxine–pyrimethamine and 
dihydroartemisinin–piperaquine (2).  
5.3.6.1 Artemether–lumefantrine 
The combination artemether–lumefantrine (AL) is currently one of the most widely used ACT, and 
has seen extensive usage in all parts of Africa, as well as in South America and parts of Southeast Asia 
(46).  
AL is a cheap, effective and well-tolerated ACT, which explains much of its popularity. However, it 
requires two doses per day, and the absorption of lumefantrine is highly dependent on co-




Artesunate–amodiaquine (AA) is another ACT currently in use in western and central parts of Africa 
as well as China and Southeast Asia, in areas with little malaria parasite resistance to amodiaquine 
(46, 51). 
Severe and potentially fatal adverse reactions such as agranulocytosis and fulminant hepatitis have 
been described when using amodiaquine as prophylaxis. However, these reactions are rare when 
amodiaquine is used in malaria treatment (55). 
Usage of AA is not recommended in areas where the 28-day cure rates of amodiaquine monotherapy 
are lower than 80%. Care should also be taken to continuously monitor resistance in areas where not 
only amodiaquine but also chloroquine is still used as monotherapy, as there is partial cross-
resistance between the two drugs (2). 
5.3.6.3 Artesunate–mefloquine  
The combination artesunate–mefloquine (AM) has been used for several decades along the Thai 
Burmese border with good effect, and the combination is regarded as safe and effective (56). The 
principle side effect is vomiting, but mefloquine also has a series of neuropsychiatric reactions, which 
are more common if mefloquine has been used in the previous two months. As such, AM should not 
be used to treat reinfections occurring within 2 months of last treatment (55). 
Recent studies have revealed high treatment failure rates (>8.8–14%) for AM in Cambodia, Myanmar 
and Thailand. The high failure rates seem to be at least partially reversible; after implementing RDTs 
to limit overtreatment and changing to another ACT, the treatment failure rates in one province in 
Thailand plummeted from 9.9–14.3% in 2002–2004 to 0–5% in 2007–2008 (46). 
5.3.6.4 Artesunate–sulfadoxine–pyrimethamine 
The combination artesunate–sulfadoxine–pyrimethamine (ASP) should only be used in areas where 
the malaria parasite sensitivity for SP is sufficiently high. This limits the usage to certain countries in 
central Asia, the Middle East, and South America. As such, this is among the least used ACTs, though 
it still has a place in the WHO treatment guidelines (2, 46). 
The continued use of SP as monotherapy and as use in intermittent preventive treatment for 





Dihydroartemisinin–piperaquine (DP) is one of the ACTs recommended as first-line treatment by 
WHO, and has been used to treat malaria for several decades, especially in South East Asia; it has 
been used as the recommended first-line treatment in Vietnam for several years (52, 57). 
Eurartesim® is currently the only formulation that meets international Good Manufacturing Practice 
standards (52). 
Studies on the combination’s efficacy have mainly been done in Asia, where they have shown that DP 
is generally non-inferior when compared to alternatives, and that it has good efficacy and good 
tolerability (52). Among the strengths that are highlighted are the drug’s relatively low price, ease of 
administration, and its low occurrence of side effects (58). More studies are needed in Africa in order 
to assess the efficacy there as well, before its use as first-line treatment can be recommended (46). 
In addition to this, some studies suggest that DP has the added benefit of yielding increased 
resistance to reinfection for some time after treatment, with lower gametocyte count and lower risk 
of recurrent parasitaemia (59). One study in Uganda found a significantly lower risk of recurrent 
parasitaemia, both newly acquired and due to a possible recrudescence of the original infection, 
when compared to using artemether–lumefantrine (60). 
Like the other 4-aminoquinolones, piperaquine has a long elimination half-life (approximately 20–22 
days), and it has been theorized that piperaquine therefore acts as a prophylactic agent as well as 
being part of the treatment itself, and that this is the reason for the lower recurrence rates using DP 
(52). If correct, this effect may be beneficial in the short term, but may over time lead to increased 
resistance to piperaquine as new parasites may be exposed to sub-therapeutic levels of the drug. 
Piperaquine resistance will in turn lead to lower efficacy of the DP drug combination (60). 
5.3.7 Iron supplementation and malaria 
The role of iron supplementation in malaria endemic areas has been controversial. Iron-deficiency 
anaemia is common in these areas, especially among children. This is in part due to repeated malaria 
infections, so giving iron supplements to children may decrease the anaemia. At the same time, there 
has been some evidence that suggests that iron supplementation may actually increase the risk of 
malaria by promoting parasite growth. However, a recent Cochrane review has concluded after 
extensive review that iron supplementation should not be withheld from children living in malaria 
endemic countries (61). More research is currently underway to assess the possible benefits and risks 
of using iron supplements in this population. 
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5.3.8 Resistance to antimalarial drugs 
Resistance to antimalarial drugs have been a major obstacle in the fight against malaria for several 
years. The first documented cases of malaria drug resistance were probably during World War II, 
where studies on soldiers taking prophylactic mepacrine (Atebrine) revealed reduced prophylactic 
efficacy of the drug. Since then, drug resistance has continued to define malaria treatment (47). 
5.3.8.1 Resistance to chloroquine and other 4–aminoquinolines  
The advent of new antimalarial drugs after World War II led to a massive shift in malaria treatment, 
from quinine and the first generation synthetic antimalarials (including mepacrine) to the more 
effective, safer and cheaper 4-aminoquinolines chloroquine and amodiaquine. Towards the end of 
the 1950s, reports of chloroquine and amodiaquine treatment failures began to surface in South 
America and South-East Asia (47). 
Part of the reason why the 4-aminoquinolones are so prone to developing resistance may be their 
long half-lives, which span from one to several months (2). This means that the parasites are exposed 
to the drugs for a long time, which in turn gives the parasites ample opportunity to develop 
resistance (52).  
The resistance to chloroquine appears to be mediated by a transport protein, PfCRT (Plasmodium 
falciparum chloroquine resistant transporter), encoded by the pfcrt gene. Parasites with mutations in 
this gene become resistant to chloroquine; the altered transport protein transports chloroquine out 
of the food vacuoles, and thereby limits the drug’s potency for blocking the detoxification of haeme 
(50).  
Genetic sequencing has revealed that there exists several different haplotypes of the mutated pfcrt 
gene, which in turn have characteristic geographic distributions, as well as drug resistance 
phenotypes (47). Genetic patterns suggest that chloroquine resistance developed at two separate 
sites; one along the Thailand-Cambodia border, then spreading to other Southeast Asian countries 
and subsequently to Africa (46, 50), while another resistant lineage developed separately in South 
America (50). 
Research indicates that different mutated haplotypes of the pfcrt gene have different fitness costs to 
the parasite. In certain areas of Africa and South-East Asia where one specific haplotype was 
abundant, chloroquine-sensitive parasites returned after a few years of discontinued use of 
chloroquine, while other areas with another haplotype still have a high degree of chloroquine-
resistant parasites to this day, even after a longer period of discontinued chloroquine usage (47). 
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The increasing resistance of P. falciparum to chloroquine and similar drugs has led to a massive 
worldwide shift in drug treatment policies for malaria. Except for a few regions, chloroquine has now 
been removed from modern malaria treatment guidelines because of the widespread resistance (47). 
Amodiaquine remains partly effective against at least some strains of chloroquine-resistant P. 
falciparum malaria; however, there does exists a partial cross-resistance between amodiaquine and 
chloroquine (2). 
Resistance against piperaquine seems to be largely unrelated to chloroquine resistance, at least in 
most areas of the world. In Africa, studies show good in vitro response to piperaquine in chloroquine 
resistant malaria parasites. However, there are high rates of piperaquine resistance in areas where 
the drug has been used extensively as monotherapy, mainly in China (52).  
The parasite resistance to amodiaquine and piperaquine is still limited enough in most areas to 
warrant their inclusion as partner drugs in ACTs in the WHO treatment guidelines (2, 46).  
5.3.8.2 Resistance to sulfadoxine–pyrimethamine 
Resistance to sulfadoxine–pyrimethamine developed soon after the introduction of the drug in 
Thailand, especially along the Thailand–Cambodia border (46), in the late 1960s; as with chloroquine 
resistance, this resistance subsequently spread to other parts of Asia and then to Africa, where 
resistant parasites were detected in Kenya in 1988 (50).  
Today, the median treatment failure rates in eastern Africa exceed 50%; in other parts of Africa, that 
number is around 20%. There are still sensitive parasites in several countries in South America, the 
Middle East and Central Asia, where the median treatment failure rate is around 5% (46). 
Resistance to pyrimethamine and sulfadoxine is mediated by mutations in the genes transcribing the 
drug target enzymes, pfdhfr (transcribing dihydrofolate reductase) and pfdhps (transcribing 
dihydropteroate synthase), respectively. Multiple mutations in these genes lead to increased 
resistance in the parasites (50). 
The tendency of sulfadoxine–pyrimethamine to cause elevated gametocytosis in the patients treated 
by the drug may lead to increased malaria transmission. This has been proposed as one explanation 
for the rapid spread of sulfadoxine–pyrimethamine resistant parasites in the world (50). 
5.3.8.3 Resistance to artemisinin and ACTs 
Parasite resistance to artemisinin represents a potentially huge challenge in the fight against malaria. 
Artemisinin and its derivatives is the primary drug used in the medical treatment of malaria in most 
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of the world today, and if extensive resistance develops, the potential ramification for public health 
is severe (62). 
As of 2010, no genetic markers for artemisinin resistance have been found, and measuring 
artemisinin resistance is therefore difficult. However, patterns of specific parasite strains have been 
found in patients with treatment failure in several studies, which indicates that there is a genetic 
basis for artemisinin resistance (46). 
As with chloroquine and sulfadoxine–pyrimethamine resistance, artemisinin resistance in 
Plasmodium falciparum parasites first appeared along the Cambodia–Thailand border. Constant 
monitoring of antimalarial drug efficacy in this area led to early detection of emerging resistance to 
artemisinin, and subsequently to an early coordinated and international response to contain the 
spread of resistant parasites (46, 62). 
5.4 Preventive measures 
In addition to treating the malaria infection adequately, malaria morbidity and mortality can be 
reduced by preventing the infection in the first place. Preventive methods can be divided into two 
main groups of intervention strategies: vector control and chemoprevention. Vector control mainly 
consists of insecticide-treated bed nets (ITNs), indoor residual spraying (IRS) and, in some cases, 
larval control. Chemoprevention is a term referring to the prophylactic use of antimalarial drugs in 
high risk groups (IPT), most often pregnant women (IPTp) or infants (IPTi) (63). The different 
preventive methods, including IRS, ITNs, larviciding and IPT will be described below, while DDT will be 
discussed on its own in greater detail in the next chapter. 
5.4.1 Insecticide-treated bed nets 
There are several categories of bed nets used to protect against mosquitoes: untreated nets and nets 
impregnated with either short-lasting or long-lasting insecticides. The short-lasting insecticide-
treated nets need frequent re-impregnation, and only a small portion of nets distributed have been 
re-treated at all (64). Long-lasting insecticide-treated nets (LLINs) are estimated to retain their 
insecticide effects for three years or longer, if used as recommended (65). Currently, only insecticides 
of the pyrethroid class are recommended for treating LLINs (63). Bed nets treated with insecticides 
works on both an individual and on a community level (63). The individual protection is caused by a 
direct protection against mosquito bites, while the community protection is a result of reduced 
mosquito density in the area (66). However, the direct effect of protection against mosquito bites 
does not solely depend on the insecticide. Guyatt and Snow argue that some of the effect attributed 
to ITNs is caused by the net themselves, not the insecticide, and present the result from a Gambian 
study where using untreated nets significantly reduced child mortality (64). 
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In several of the articles reviewed, both short-lasting and long-lasting insecticide-treated nets were 
compared together against untreated nets or using no nets at all. When used below, the term ITN 
will therefore include both kinds of insecticide treatment, both short-lasting and long-lasting ITNs, 
unless otherwise specified. 
Several studies have evaluated the effect of bed nets, and ITNs in particular, in sub-Saharan Africa. In 
their meta-analysis, Choi et al. found that utilization of ITNs gave a significant reduction in malarial 
incidence, both when compared to untreated nets and no usage of nets (67). A review of studies 
from areas with endemic P. falciparum malaria estimated that ITNs to have a protective efficacy of 
17% on malaria prevalence in children. They also found ITNs to reduce the incidence of 
uncomplicated malaria among children by half (68). 
Using ITNs compared to not using nets is also associated with reduced incidence of placental malaria, 
regardless of parity (69). Among women in their first pregnancies, ITN usage has been shown to have 
an effect on the incidence of LBW, stillbirths and abortions (69). Eisele et al. have estimated that ITN 
usage alone can help reduce LBW in paucigravidae in endemic P. falciparum settings (68). 
There are also promising estimations of effect of ITNs on child mortality in sub-Saharan Africa. All-
cause mortality for children under five years has an estimated reduction of 18% (68-70). Mortality 
caused by malaria among children 1–59 months of age is estimated to be reduced by 49–60% when 
compared to not using nets at all (68).  
Noor et al. mapped the ITN coverage between 2000 and 2007 in sub-Saharan Africa. They found that 
in areas of stable transmission, only 1.8% of children slept under an ITN in 2000. By 2007, this had 
increased tenfold to 18.5% (71). The largest improvement took place in areas where ITNs had been 
distributed free of charge between 2000 and 2007 (71). 
Distribution campaigns in several countries have tried to increase the ITN coverage. In Sierra Leone, 
the proportion of households with at least one ITN increased from an estimated 37% in 2008 to 
87.6% in 2010, after a national campaign distributing ITNs for free (72) , while Tanzania saw an 
increase from 62.6% to 90.8% of households with at least one ITN after a similar distribution 
campaign (73).  
The use of ITN among those in households with at least one net, were 76.5% (72). In Cameroon, a 
survey found that 59.7% of households had ITN, but that only 42.6% of the households in the country 
used ITNs (74). Among households in Ethiopia with at least one ITN, the usage among pregnant 
women and children under five was 52.1% and 63.0%, respectively (75). 
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Surveys have found several factors associated with ITN usage. Bennet et al. found the use of ITN was 
associated with knowledge of how malaria is transmitted, whether they were reached by public 
information about malaria, and the availability of nets (72). 
Koenker et al. found that the youngest children were generally prioritized for sleeping under ITN. In 
households with an ITN, 93% of children beneath 23 months of age and 92% of children between 24 
and 35 months of age slept under an ITN. The rates for older children were lower, at 55% among 
children at 5 years of age (76). This correlates to findings in other studies, where increased number 
of children reduced the probability that a child slept under an ITN (77, 78). 
A survey two years after a distribution campaign found that ITN usage was associated with how 
many ITNs they had in the household, how easy they could use the nets, and the women’s 
knowledge about the nets (75). In Ghana, the use of nets was also associated with knowledge of 
malaria transmission method, the number and the conditions of nets in the household. It was also 
associated with the colour of the net and whether the net had been received free of charge, or if it 
had been bought. The authors suggest that subsidizing nets in the commercial marked may increase 
the usage among those who can afford to buy them (79). 
5.4.2 Indoor residual spraying 
Indoor residual spraying (IRS) is a vector control method based on the application of insecticide on all 
surfaces inside buildings within the target area. Vectors are killed if they come in contact with the 
insecticide, and in some cases mosquitoes also are repelled from entering the building. These 
mechanisms reduce human exposure to mosquitoes and thereby reduce malaria transmission. Some 
Anopheles species mainly rest and bite outside, such as An. arabiensis, and are therefore less 
affected by IRS. It is effective against vectors indoors, such as the common An. gambiae (80). As IRS 
mainly reduces the number of mosquitoes leaving the house, the intervention protects the 
community rather than the individual, in contrast to bed nets (81). In areas where IRS is utilized, 
spraying coverage above 80% should therefore be attained to reach the intended effect (80). IRS is 
performed by manually spraying insecticide on walls and ceilings with hand-operated compression 
air sprayers, preferably ahead of transmission season. 
IRS has earlier been used with good results in many parts of the world, especially connected to the 
Malaria Eradication Programme that was executed in several malaria-endemic parts of the world 
between 1955 and 1969, where malaria was eliminated from several countries worldwide. This 
programme was not implemented in most of sub-Saharan Africa, however (80). 
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After the first decades of insecticide usage in malaria vector control, a period with declining 
utilization followed, despite the results that were achieved. According to WHO, this reduction may be 
partly caused by inadequate national prioritization, apprehension of the developing resistance and 
public approval. The latter especially applies to DDT, which was globally scorned (80). During the last 
decade however, the insecticide-based vector control has increased dramatically. In 2010, the 
number of LLINs distributed in Africa was 25 times higher than in 2004, while the number of people 
protected by IRS was almost eight times higher than in 2005 (81). 
There are several insecticides that can be used for IRS, including organochlorines (e.g. DDT), 
organophosphates, carbamates and pyrethroids. The safety and efficacy of these are constantly 
being evaluated by WHO (80). Pyrethroids are the most commonly used insecticides today, both for 
IRS and ITNs (82). The different insecticide classes also have different duration of insecticidal effects. 
Organophosphates and carbamates have the shortest duration, which in turn means that they 
require frequent spray cycles in order to achieve optimal coverage. The costs associated with the 
different insecticides when used in IRS also differ, with DDT and pyrethroids being the cheapest (80). 
The efficacy against local vectors is affected by the local insecticide resistance, which reduce the 
vector’s susceptibility toward the insecticide (80), described in detail below. In order to ensure the 
safety of the population and the environment in target areas, adherence to recommendations on 
administration and handling of the insecticide is important (80). 
5.4.3 Insecticide resistance  
As mentioned earlier, pyrethroids are used in both IRS and ITNs, and make pyrethroid resistance a 
pressing concern when it comes to vector control. Pyrethroid resistance in malaria vectors is 
widespread (80), and has been confirmed in 27 countries in sub-Saharan Africa as of 2010 (82). 
Additionally, resistance towards carbamates and organophosphates has been seen in West Africa 
(80). 
Pyrethroid-resistant vectors have two known resistance mechanisms, and it is probable that other 
mechanisms exist. The first resistance mechanism is often called knockdown resistance (kdr); it is a 
mutation in the target site for the insecticide, which is located on the insect nerve membrane. The 
other resistance mechanism is a mutation that increases the metabolizing rate of the insecticide (82)  
Because insecticides share many of the same modes of action, resistance towards one class of 
insecticide frequently results in resistance towards other classes as well. For example, the 
widespread kdr mutation gives cross-resistance between pyrethroids and organochlorines. In 
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addition, cross-resistance between organophosphates and carbamates has been reported in West 
Africa (82).  
Insecticide resistance has developed after exposure to the use of insecticides in either agriculture or 
in IRS, as the usage of the same insecticide in both agriculture and IRS in the same area may increase 
the selection pressure. In some cases, agriculture has clearly contributed to resistance development 
among vectors in an area, while IRS is clearly responsible in others. Agricultural impact on resistance 
has especially been a problem in areas where cotton and rice are cultivated. Collaboration with the 
agricultural sector is therefore useful to limit the development of resistance, so that different 
insecticides should be chosen in agriculture and in vector control, preferably by using an agricultural 
insecticide that is not recommended for use in IRS (82). 
The knowledge about how insecticide resistance affects malaria vector control is scarce, in addition 
to inconsistency between the few available reports. ITNs have been observed to remain effective, 
while the efficacy of IRS has been reduced over time (82). 
5.4.4 Larviciding 
A third option for vector control is anti-larval methods that inhibit mosquito breeding, including the 
use of larvicides (83). As this method reduces the number of adult mosquitoes, it reduces the risk of 
bites both indoors and outdoors (83). To be effective, larvicides need to be applied to a high 
proportion of mosquito breeding sites within flight area of the targeted human dwelling. Typical 
breeding sites differ between different Anopheles species, and range from semi-permanent sites to 
temporary pools of water, such as flooded foot prints (84). Therefore, this method requires more 
local knowledge regarding the Anopheles species in the area compared to other vector control 
methods (84). 
Larviciding is most useful when the local breeding sites are known and few in number, so as many 
breeding sites as possible within the estimated flight range should be eliminated. Other local features 
that may increase the likelihood of success with larviciding include lower temperatures, seasonality 
and breeding sites that are easy to eliminate. As lower temperatures delay the metamorphosis from 
larva to adult mosquitoes, colder areas are easier to manage. The maturation period normally takes 7 
to 10 days, which demands weekly elimination for optimal effect. Larviciding may be effective when 
used thoroughly (85), and was the method used for elimination Anopheles arabiensis from Brazil and 
Egypt (86). The utilization of IRS and ITNs may result in a remaining problem of resistant vectors and 
vectors that mainly bite outdoors. Worrall and Fillinger indicate that the role of larviciding may 
increase in such settings (83). 
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5.4.5 Intermittent preventive treatment 
Intermittent preventive treatment (IPT) is a preventive strategy focusing on high risk groups, where 
antimalarial treatment is given regularly, independently of whether a person has malarial infection or 
not (69). The goal of IPT is to clear the parasitaemia, regardless of whether it gives symptoms or not, 
and to give some prophylaxis against new malaria infections (36). 
Chemoprevention is mainly given during pregnancy (IPTp), but can also be given to infants (IPTi) and 
children (IPTc). Several qualities are wanted in a drug used for IPT. First, it must be safe to use in the 
respective patient population, and ideally have few adverse effects. Second, it should be effective 
with high parasitaemia clearance and preferably some added chemoprotective effect in the period 
following the treatment. Third, it should be a realistic possibility to offer the drug to the 
communities, with regard to economic factors as well as drug stability and community acceptance. 
Finally, an ideal IPT drug should be different from the drug used for first-line treatment, to reduce 
the selection pressure on the drugs and delay or prevent the emergence of resistance (31, 36, 87). 
5.4.5.1 Intermittent preventive treatment in pregnancy 
As stated earlier, studies have associated malaria infection during pregnancy with an increase in 
infant mortality and morbidity through maternal anaemia, infant anaemia, LBW, stillbirth and 
spontaneous abortion. In areas of stable transmission of P. falciparum, 30% of preventable cases of 
LBW can be attributed to maternal malaria infection (70). Therefore, preventing maternal infection 
may be one way of increasing infant health. To achieve this, WHO recommends the use of ITNs to 
pregnant women in areas of malaria transmission, as well as IPTp to pregnant women in P. 
falciparum endemic areas (3). 
Vanga-Bosson et al. found that using SP as IPT was associated with decreased placental parasitaemia 
in Côte d’Ivoire. The tendency of reduction in placental parasitaemia was larger if the women 
received two doses of SP instead of one. They also revealed that children of mothers with placental 
parasitaemia had significantly higher prevalence of LBW (35). A Cochrane review found significant 
effect of antimalarial drugs used as IPTp or chemoprophylaxis on placental infection, but not on LBW 
in all-parity trials (88). 
Administration of IPTp to paucigravidae is associated with decreased incidence of LBW, when 
compared to not using IPTp or other chemoprophylaxis (88). Eisele et al. estimated in their review 
that the protective efficacy on LBW for IPTp and the use of ITN to be 35% among paucigravidae in 
stable P. falciparum transmission areas (68). A different review found a relative risk of 0.71 among 
paucigravidae in areas of SP resistance and ITN usage (68). Garned and Gülmezoglu estimated that 
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IPT or prophylaxis might reduce perinatal mortality in paucigravidae, as well as the incidence of 
anaemia and severe anaemia, compared to no chemoprevention (88). 
The timing of IPTp is usually not based on the gestational period, but rather on the safety of the drug 
that is used. SP is regarded as safe in the second and third trimesters, but is avoided close to term 
because of concerns that sulpha drugs may give kernicterus in premature new-borns (30). This has 
not been seen clinically, even though SP has been widely used close to term and in new-borns for 
symptomatic treatment of malaria and toxoplasmosis. Even though SP is considered safe, it should 
not be administered together with co-trimoxazole, a prophylactic drug given to HIV-infected, as 
these two drugs interact and give increased adverse effects (89). 
SP has folate antagonistic effect, a drug mechanism that often is associated with an increased risk of 
neural tube defects if pregnant women are exposed in first trimester. An increase in congenital 
defects when SP is given after foetal quickening has not been reported. Pregnant women are 
recommended to take folic acid supplementation (0.4 mg/day), a dosage that will not limit the 
antimalarial effect of SP, even though high doses of folic acid supplement may reduce this effect (89). 
There are concerns regarding the effect of using SP for IPTp because of the increasing resistance 
towards SP. During the last decade, several trials have evaluated alternatives to SP as IPTp. A trial in 
Ghana in 2008 compared amodiaquine, SP plus amodiaquine, and SP given as IPTp. They found 
similar rates of anaemia and LBW between the three alternatives, with a significant reduction of 
prevalence from enrolment to delivery for both parameters. However, the women who received 
amodiaquine alone or SP plus amodiaquine had higher incidence of adverse effects, reaching 
statistical significance (90). 
In their review, Garner and Gülmezoglu found one trial from 1991 where proguanil gave fewer 
episodes of fever and less parasitaemia among all-parities compared to chloroquine. SP reduced the 
incidence of LBW and maternal parasitaemia compared to chloroquine in low-parity women, 
estimated from two trials from 1994 and 2005 (88). 
Azithromycin is a macrolide that has been used to treat bacterial infections in pregnancy, and thus 
has been considered safe to use during pregnancy. Azithromycin–chloroquine and mefloquine seem 
to have similar effect on clearance of P. falciparum. Both can be given earlier in pregnancy than SP, 
which may increase their effect during pregnancy (36). 
Since azithromycin is an antibiotic drug, it has an effect on other infections than malaria, such as 
sexually transmitted diseases and pneumococcal infections. The former is known to increase the risk 
of several parameters for reproductive health, such as prematurity, birth weight and perinatal 
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mortality. This effect may therefore add to the health benefit from malaria reduction. The effect on 
S. pneumoniae may become a problem because of the risk of increased resistance towards 
azithromycin or even development of cross-resistance with erythromycin. Chico et al. therefore 
conclude that trials regarding prevention with azithromycin should keep pneumococcal resistance 
under surveillance (36).  
Mefloquine has maintained efficacy for treatment and prevention, with effect on parasitaemia and 
LBW among pregnant women (31). McClure et al. found chloroquine and mefloquine to affect 
placental infection in a similar degree as SP used as IPT (91). Several studies on the safety of 
mefloquine during pregnancy have not found any serious adverse effects, but a few small trials have 
shown a tendency of increased rate of stillbirths (31). The overall evidence still suggests that 
mefloquine is safe during pregnancy (92). 
5.4.5.2 Intermittent preventive treatment in infancy 
A meta-analysis of the effect of SP as intermittent preventive treatment in infancy (IPTi) showed 
promising results, with an effect on clinical malaria at 30.3%. They also estimated a protective 
efficacy of 21.3% against anaemia (93), even though only three of the seven trials included had a 
significant effect on anaemia alone (94). 
In Tanzania, one study found reduced incidence of malaria infection by 60% and anaemia by 50% for 
infants given SP as IPTi (95). Another study from a different area of Tanzania found that amodiaquine 
used as IPTi gave similar effects on clinical malaria and anaemia (96). However, Gosling et al. found a 
significant effect on clinical malaria only for mefloquine in their trial, not for SP or chlorproguanil–
dapsone. The lack of effect for SP may illustrate the effect of high SP resistance, since the latter trial 
was carried out in an area where SP efficacy was estimated at 18% (97).  
Menéndez et al. found that IPTi with Deltaprim (pyrimethamine and dapsone) had a protective 
efficacy of 57.3% against severe anaemia and 60.5% against all malaria during the intervention 
period (98). Chandramohan et al. also found a significant reduction of malaria episodes and anaemia 
in their IPTi trial in Ghana, as well as a reduced number of hospital admissions caused by malaria. The 
intervention group in this trial was given SP at vaccination visits and at 12 months of age, but the 
effects above maintained significance the first 15 months of age (99). A trial on weekly prophylaxis 
with Deltaprim during infancy also found a reduced risk of clinical malaria, anaemia and severe 
malaria among the intervention group during the time of prophylaxis (28).  
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5.4.5.3 Chemoprevention for older children 
In areas of seasonal transmission, several trials have been done regarding chemoprevention to 
children after infancy. A review by Wilson found that IPT given monthly to children during 
transmission season had a significant effect on reducing episodes of clinical malaria, when estimated 
from the results of several trials from Sahel and sub-Sahelian areas. IPT also reduced the all-cause 
mortality in the intervention groups in the period of peak malaria transmission (100).  
A trial in Senegal, where children under ten years of age received the combination of SP and 
amodiaquine each month during the peak transmission period, found reduced prevalence of 
parasitaemia and anaemia in the intervention group compared to the control group (101).  
The tendency of reduced anaemia risk among the interventions groups in areas of seasonal 
transmission was also found in a review by Meremikwu et al. In this review, they also estimated IPTc 
to reduce the risk of clinical malaria and severe malaria. These results are also maintained in two 
studies with high ITN coverage (102).  
Kweku et al. compared the effects of different IPT combinations to placebo in children 3–59 months 
of age in Ghana. They found that both monthly or bimonthly artesunate–amodiaquine and bimonthly 
SP gave significant results in reducing clinical malaria and anaemia (103).  
A trial from Uganda, however, found that IPT with SP gave the same risk of parasitaemia as placebo 
while amodiaquine plus SP and dihydroartemisinin–piperaquine both reduced the risk of 
parasitaemia in children between 8 and 14 years of age. The prevalence of five molecular markers for 
SP resistance, including pfdhfr and pfdhps, was over 80% in the area of this trial (104). 
In the twelve trials reviewed by Wilson, no serious adverse events were reported (100). There were 
not seen any serious adverse effects in neither of the trials review by Meremikwo et al. either; 
however, the combination of SP and amodiaquine has been seen to increase vomiting in children 
(102). 
5.4.5.4 Rebound effect 
Studies on immune response among pregnant women have shown reduced levels of malaria specific 
antibodies in women using preventive measures, both with ITN and IPTp. The severity of malaria 
infection during pregnancy shows parity dependence in endemic areas, with more severe disease in 
primigravidae. Whether this effect will be maintained in settings with high levels of prevention 
during pregnancy is uncertain (30). 
 
33 
The positive effect of IPT seems to be limited to the period of receiving the antimalarial drug. Several 
studies have shown an increase in incidence of malaria episodes after completion of IPTi, called a 
rebound effect (98, 105, 106).  
Dicko et al. however, concluded that children receiving IPT did not have increased risk of malarial 
parasitaemia or malarial complications the following season, even though an increase in the 
incidence of clinical episodes of malaria may be seen (106).  
A trial on IPTi in Tanzania found that the intervention group had significantly higher incidence rates 
for malaria episodes and severe anaemia in the year after discontinuing IPT. They did not find any 
difference in the severity of malaria episodes when comparing parameters on severity from the 
episodes in the intervention and control groups (98). 
One trial where weekly chemoprophylaxis was given during infancy found that the incidence rate 
remained significantly higher in the intervention group the first 18 months after discontinuing 
prophylaxis. They did not find significant differences three years after discontinuing the prophylaxis. 
There was a tendency of higher cumulative incidence for clinical malaria in the intervention group, 
while there was a lower tendency for severe malaria in this group (28). 
An immunological trial on antibody response to malaria in preschool children receiving IPT found that 
the IgG levels towards schizonts of P. falciparum was reduced by 33% in the intervention group 8 
months after the last IPT dose. The antibody level was strongly associated with prevalence of present 
parasitaemia or history of clinical malaria previously, regardless of treatment received. They suggest 
that the effect of IPT on immunological response may be caused by a reduction in exposure, rather 
than through a direct effect on the immune system. This hypothesis is supported by research findings 
where IPTi shows no impact on the vaccine response among infants (107). 
Dicko et al. found similar incidence rates in those who had received IPT with SP and those receiving 
placebo the year after intervention (108). Two review articles from areas of seasonal malaria 
transmission did not find significant increase in incidence rates the year after IPTc (100, 102). Wilson 
remarked that three studies in her review had a tendency to an increased incidence rate among 
intervention groups the year after IPT, but that none of the studies had significant results (100). 
In a Gambian study, they followed children who had received IPT with dapsone plus pyrimethamine 
until they turned five years of age. The incidence rate for clinical malaria was higher in the 
intervention group the first years after chemoprophylaxis was discontinued, but the two groups had 





In this chapter, we will take a closer look at DDT, how it is used, as well as how it affects insects, the 
environment and at its potential ramifications for human health. After this, we will look at what kind 
of effect DDT had 50 years ago, and the road from being a celebrated pesticide to facing increasing 
scrutiny, leading to its eventual ban. The first part is mainly based on the “Toxicological Profile for 
DDT, DDE and DDD” from 2002, made by the Agency for Toxic Substances and Disease Registry, a 
subset of the United States Department of Health and Human Services. The historical perspectives 
are mainly based on the book DDT, Silent Spring, and the Rise of Environmentalism by Thomas R. 
Dunlap. 
DDT stands for 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane, a synthetic chemical that was first 
synthesized in a German laboratory in 1874 (4). It is a white crystalline chemical without taste or 
odour. DDT biodegrades slowly into DDE (1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene) and DDD 
(1,1-dichloro-2,2-bis(p-chlorophenyl)ethane) (110). 
5.5.1 How DDT enters the environment 
DDT enters the environment during both production and use. In the past, vast amounts of DDT have 
been sprayed on crops and in forests in order to control insects, releasing large amounts of DDT into 
the air, soil and water. Therefore, most of the DDT in the environment is a result of past use, though 
DDT continues to enter the environment in areas where it still is manufactured and applied (111). 
In addition to the direct dispersion into the air when sprayed, DDT may also enter the air through 
evaporation from contaminated water and soil, which can then be deposited on new land or water 
surfaces. In this way, DDT can be widely spread throughout the atmosphere, resulting in 
contamination far from the places it originally was applied; even though DDT has mostly been used in 
warm or temperate climates, traces of DDT has been found in Arctic and Antarctic regions (111). 
Because of the slow biodegradability of DDT, any DDT that enters the environment lasts for a long 
time, potentially for several hundred years. In the USA, the Environmental Protection Agency (EPA) 
has put together the National Priorities List (NPL), which is a list of what is considered to be the most 
serious hazardous waste sites in the nation. People living or working in near vicinity with the sites 
identified in the NPL are at high risk of being exposed to DDT, either through soil, dust or vapours 
containing the chemical (111).  
5.5.2 How DDT enters the body 
The main way DDT enters the body is through contaminated food, but small amounts of DDT may be 
breathed in as well. Because DDT is frequently attached to large particles in the air, DDT does not 
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usually enter the alveoli in the lungs, but rather becomes stuck in the mucous and swallowed. DDT 
does not pass through skin easily. Therefore, the majority of the DDT that enters the human body 
enters through the gastrointestinal tract (110). 
5.5.3 The effect of DDT on insects 
DDT is an insecticide, which means that it is toxic to insects. It primarily acts on the nervous system 
of the insect, with a slightly delayed action; after contact with an oily DDT solution, it takes about 
twenty minutes before an observable effect on the insect. By inhibiting the nervous system of the 
insect, it induces spasms and paralysation, which eventually kills the insect (4). 
5.5.4 How DDT, DDE and DDD can affect human health 
DDT and its metabolites, DDE and DDD, have been measured in human fat tissue, as well as many 
bodily fluids, including blood, urine, semen and breast milk. However, most of the data on the human 
toxicity of DDT comes from animal studies (111). 
Acute toxicity has been seen in people exposed to large amounts of DDT, with excitability, tremors 
and seizures, in addition to more benign symptoms such as sweating, headache, nausea, vomiting 
and dizziness. These effects were reversible, and went away after exposure was stopped. These 
effects are explained by experiments on laboratory animals, which have shown that DDT has a toxic 
effect on the nervous system in animals as well as insects (111). 
There is little information on the long-term effects of chronic DDT exposure in humans. One study 
where low-dose DDT (35 mg) was given to adults daily for 18 months showed no significant effects. 
However, long-term exposure of less than 20 mg DDT daily, for example in DDT factory workers, has 
been correlated with minor changes in liver enzymes, but not with an increase in mortality or cancer 
(111).  
Current knowledge about the long-term effects of chronic DDT exposure is therefore mainly based 
on animal studies in addition to a few human studies. Several studies have shown that chronic 
exposure to moderate levels of DDT is potentially hepatotoxic in animals, as well as having 
detrimental effects on reproductive health and negatively affecting the adrenal gland. DDT has been 
classified as a possible human carcinogen based on animal studies (111). 
5.5.4.1 The effect of DDT on reproductive health and in infants 
As mentioned above, studies have shown that DDT negatively affects reproductive health in animals. 
This may be partially explained by the fact that DDT and its metabolites display weak oestrogenic and 
anti-androgenic effects (111). Studies have shown that DDT slows the growth of the reproductive and 
nervous systems in the foetus, and exposure during pregnancy is associated with pre-term labour; 
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this has been substantiated in one human trial as well, where an elevated level of DDE in pregnant 
women was correlated with prematurity. Another human trial found an association with DDE 
concentrations in breast milk with decreased duration of lactation period (111).  
In addition, several studies have shown detrimental long-term effects when animals have been 
exposed to DDT or its metabolites early in life. One study observed the delayed puberty in male rats 
exposed to DDE during adolescence; other studies have shown changes nervous system 
development, with decreased neurological performance later in life. These findings have raised 
concerns that DDT exposure during early life may have detrimental effects on development in 
humans as well (111). 
As previously noted, DDT has been found in most bodily fluids, including breast milk, and this 
represents another way children can be exposed to DDT. However, EPA concludes that the potential 
risks of DDT exposure are offset by the benefits of breastfeeding (111). 
Ultimately, there is little solid information about the effects of DDT on human pregnancy and 
childhood, though animal studies indicate that there are some potentially serious harmful effects 
when exposed to moderate or high doses of DDT. One complicating factor is that DDT concentrations 
tend to be higher in children compared to adults because of the size; one study from 1985–1991 in 
the USA observed that 8.5 month-old infants had 4 times higher concentrations compared to adults 
(111). 
5.5.5 The history of DDT 
The book DDT, Silent Spring, and the Rise of Environmentalism by Thomas R. Dunlap is a collection of 
excerpts from a variety of sources. Texts from scientific studies, government reports, advertisements 
from industry journals, articles from popular magazines, and an excerpt from the book Silent Spring 
by the American environmentalist Rachel Carson, gives an impression about the early success of DDT, 
the discovery of its environmental effects and the shifting attitudes toward DDT as well as pesticides 
in general. In addition, the book also contains some information about the recent debates about 
using DDT as a potential measure to fight malaria in Africa. 
5.5.5.1 The DDT revolution 
Even though DDT was originally synthesized in Germany in 1874, its insecticide properties were 
unknown until the late 1930s when chemists in Switzerland began testing synthetic organic 
compounds in the search for new pesticides. It was quickly discovered that it was very effective in 
killing insects, and it seemed reasonably safe to humans as well. The compound was named DDT, and 
became widely used in World War II to combat insect-borne diseases in the Pacific Ocean theatre 
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and typhus-carrying lice in the European theatre. In addition to dusting soldiers with DDT, the 
chemical was used extensively in civilian life; housewives sprayed their houses to make them insect 
free, and farmers sprayed DDT on their fields and on animal houses (4, pp. 4-5).  
During and after World War II, the benefits of DDT were well known. Besides its applications in 
agriculture and in civilian life, it was also a great tool for limiting the spread of disease-carrying 
insects, such as mosquitoes carrying malaria and lice carrying typhus. In the text “How Magic is 
DDT?” from early 1945, Brigadier General Simmons writes that DDT played an important role in the 
war by controlling malaria among allied troops. Malaria had been a major burden during earlier war 
efforts, and any means that could help control the disease and reduce the prevalence were very 
valuable. He further states that the strategic value of controlling malaria and typhus was only 
scratching the surface of the true potential of DDT (4, pp. 36-38). 
Following the extensive use in the 1940s, the Surgeon General’s Office of the United States Army 
requested that the potential toxicity of DDT should be assessed; however, the study found that, with 
the exception of massive exposure leading to acute toxicity, no definite evidence of adverse effects 
following normal use were found (4, pp. 26-28). 
Even though DDT was widely celebrated, some began to investigate the potential ramifications of its 
use more closely. The rapid implementation and massive production of DDT without first assessing 
the potential long-term effects of its use, gradually led to increasing doubt about its safety (4). 
5.5.5.2 Discovering and publicizing the harmful effects of DDT 
Studies from the late 1940s showed that essentially all Americans had been exposed to DDT in some 
form. DDT had been used extensively without knowing how it entered and affected the environment, 
and without knowing how it could be handled and potentially cleaned up. Experiments started to 
show that DDT was stored in the fat of animals, and that long-term exposure to relatively small 
amounts of DDT eventually led to liver failure. These studies, indicating potential toxicity in animals, 
raised the possibility of toxicity in humans as well. Despite the results of these preliminary studies, 
the Food and Drug Administration in the USA concluded that the potential benefits of DDT 
outweighed the risks involved (4, pp. 52-55). 
By the late 1950s, the amount of DDT in the soil, water and atmosphere reached critical levels, and 
its effect on the environment became more and more clear. Robins were dying in large numbers, and 
the forests became noticeably quieter as songbirds died off; despite increasing public attention, 
massive spraying campaigns continued. The dead robins were studied, showing the cumulative effect 
of DDT on the food chain, raising further concerns for human health (4, pp. 4-5). By the early 1960s, 
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the same effects were seen in peregrine falcons throughout North America and Europe, with a sharp 
decrease in the population. Research showed that peregrine falcon eggshells contained DDT (4, pp. 
68-74) and were thinner than normal, and it was theorized that this was due to a change in calcium 
metabolism of the birds (4, p. 84). Additionally, in the late 1950s, signs of DDT resistance in 
mosquitoes started to appear. In addition to the possible detrimental health effects of DDT, this 
signified the need for basic research (4, pp. 89-90). 
Rachel Carson released Silent Spring in 1962, a book that quickly became a best-seller and that would 
permanently change the public attitude towards DDT. In addition to some research showing the 
potential toxicity of DDT, it also contained a lot of anecdotal and circumstantial evidence, including 
examples such as disappearance of birds and bees, as well as the reported frequency of illnesses 
among farmers, their families and their animals (4, pp. 102-103). 
Even though public opinion had already shifted, the scientific view was more cautious; even though 
the available evidence gave cause for concern, most scientists were not ready to come out against 
DDT, because too little was known about the potential harmful effects of DDT (4, pp. 82-83).  
Following the massive shift in public opinion after the publication of Silent Spring, President Kennedy 
asked for a report from his Science Advisory Committee. This report, finished in 1963, verified the 
claims that DDT persisted for a long time in the environment, and that it could spread from one 
ecosystem to another. It also stated that there was too little information to make any definite 
conclusions when it came to the potentially harmful health effects of DDT, and recommended that 
further studies should be performed in order to assess the levels of exposure in the population, as 
well as the long-term effects of DDT exposure (4, pp. 104-108). 
The Environmental Protection Agency (EPA) was founded in 1970; in 1972, this organization banned 
all domestic use of DDT in the USA with the exception of public health emergencies. Because of 
environmentalist pressures from the USA as well as increasing insecticide resistance, the use of DDT 
declined worldwide throughout the 1970s. By the 1990s, the use of DDT reached an all-time low; at 
the same time, malaria rates in tropical countries were on the rise. This led to a debate whether or 
not Africa could benefit from using DDT as well (4, p. 9). 
5.5.5.3 Is there still a role for DDT? 
Despite the mainstream popularity of Silent Spring, the book also met widespread criticism from 
several sources. Some have criticized the book for using a simple and elegant language to convince 
people of the dangers of DDT (4, p. 113), while at the same time ignoring the benefits that DDT has 
achieved. In addition to leaving out many of the positive effects DDT has had since it was first used, 
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Carson also establishes a link between DDT and cancer, hepatitis and mental disorders, without 
having the scientific evidence to back these claims up. Some have criticized the book for taking a 
one-sided stance in the cases it focuses on. For instance, the book brings up the increase in cat 
deaths following an antimalarial programme carried out by WHO in Indonesia, but fails to look at 
how many lives were potentially saved by this programme. DDT was used because earlier eradication 
programmes had dubious effects at best; in addition, it was easy to use, effective and inexpensive (4, 
p. 125). 
There are several different views on DDT today, but most seem to agree that DDT can be used in 
certain circumstances. While some lay the blame for the increase in malaria increase in developing 
countries on the international ban on DDT (4, pp. 127-128), others feel that DDT is a tool and not a 
solution. Large organizations such as WHO conclude that DDT can be considered a temporary tool, to 
be used with caution in the fight against malaria, and only when the benefits clearly outweigh the 
risks (4, pp. 136-139). 
5.6 Malaria in the world 
According to the Global Health Observatory, malaria occurs in 99 countries (112). In 2011, there were 
a total of 26 million reported malaria cases and 106,820 reported deaths worldwide caused by 
malaria. However, the real burden of the disease is probably much larger than the reported numbers 
indicate (113). 
There has been an estimated global reduction of 25% in the malaria mortality rate over the last 
decade. Some of the most important reasons for this are the large interventions when it comes to 
vector control, diagnostics and treatment (114). In sub-Saharan Africa, ITN coverage has increased 
rapidly over the last decade, and was over 50% in 2011. Nevertheless, the ITN distribution is still 
insufficient to provide universal coverage in the population (115). The number of diagnostic tests has 
also increased greatly over the last years, and in 2011, statistics showed that diagnostic tests were 
used in three out of four suspected malaria cases worldwide; however, WHO implies that this 
number may be too high, because it depends on countries reporting their usage (116). 
However, the progress in the fight against malaria the recent years has now slowed down as a result 
of the development of resistance against antimalarial drugs and insecticides, as well as the 
stagnation of funding. Addressing these problems is important to keep reducing the burden of the 
disease globally (114).  
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5.7 The World Health Organization 
To get a better understanding of how the World Health Organization (WHO) is organized and how it 
can help countries in the fight against malaria, we first want to present the organization itself, and 
describe some of their more relevant programmes. 
WHO is a part of the United Nations (117), and was established in 1948 (118). The organization works 
globally to improve health worldwide through technical support and guidance to nations, as well as 
monitoring global health and promoting research on health issues (117). 
WHO strives to make essential health care available to all, especially targeting vulnerable population 
groups in the world, and use impact on women’s health and African health as parameters of their 
influence (119). 
To achieve this, several aspects affecting health are targeted, including access to health services and 
ensuring its quality, as well as presenting health information and recommendations. Factors like 
having adequate human resources and solid access to drugs and equipment are important to 
improve the quality of the health care systems. Vulnerable groups are especially targeted, and 
interventions are prioritized to areas where they might give the most benefit (119). 
WHO publishes the World Health Report, where statistics on specific subjects regarding global health 
are presented (120). 
5.7.1 The WHO Global Malaria Programme 
The WHO Global Malaria Programme administrates WHO’s efforts against malaria. They present 
recommendations and monitor malaria statistics globally, as well as publishing the annual “World 
Malaria Report”. The programme addresses different aspects of fighting malaria, and give guidance 
that can be used in national malaria programmes (121). 
5.7.2 Roll Back Malaria partnership 
The main goal of the Roll Back Malaria (RBM) partnership is enhancing the fight against malaria 
through coordinating different interventions. It was established in 1998, and has over 500 partners 
worldwide, including the main actors WHO, United Nations Children’s Fund (UNICEF), United Nations 
Development Programme (UNDP), and the World Bank. RBM attempts to coordinate the utilization 
of resources to increase their worth, and thereby reduce the malaria burden globally (122).  
5.8 The WHO malaria guidelines 
WHO has given out guidance to assist countries in their fight against malaria, including diagnosis and 
treatment, chemoprevention during pregnancy, infancy and childhood, vector control with focus on 
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ITNs and IRS, as well as managing resistance towards antimalarials and insecticides. In addition, 
guidelines for surveillance and persistent evaluation is important to sustain the effectiveness of the 
guidelines, and make new guidelines where it is needed (3). 
5.8.1 Recommendations in diagnosing malaria 
Diagnostic tools like microscopy and RDTs, when used in combination with efficacious treatment, 
allow for effective case management. WHO states that parasitological diagnosis should be sought 
before starting the treatment (3). Nevertheless, treatment should not be postponed more than two 
hours while waiting for the confirmation of the diagnosis (123). The parasitological diagnosis should 
preferably be performed using microscopy, but RDTs can be used when this is not available (3). As 
described earlier, clinical manifestation is rarely distinctive and parasitological verification is 
therefore needed. In settings where microscopy or RDTs are unavailable, treatment can be started 
on clinical suspicion. This may lead to excess use of antimalarial drugs and postponed treatment of 
other febrile illnesses (3). 
5.8.1.1 Guidelines for microscopy 
Microscopic diagnosis is recommended if adequate quality of microscopy services is available. Even 
though parasitological diagnosis using confirmation is used at some larger health care institutions, 
the quality is not always adequate. To improve the standards, WHO has given guidelines regarding 
microscopy, as well as for the monitoring of this diagnostic method in order to ensure that it is 
utilized correctly. For a microscopy service to be regarded as adequate, a good quality diagnosis 
should be given within an acceptable timeframe, which in turn require having all necessary resources 
available. In order to ensure optimal quality of diagnosis, the operating technicians should be trained 
and educated. WHO proposes that a mandate should be established to ensure the implementation of 
these requirements (3). 
5.8.1.2 Guidelines for rapid diagnostic tests 
As mentioned above, WHO states that parasitological diagnosis should be sought before starting the 
treatment, and RDTs are an option in settings without access to adequate microscopic diagnosis (3). 
These tests have become more frequently available and utilized over the last years (124). 
Limited knowledge regarding the test qualities made implementing their utilization in guidelines 
more difficult, especially since results from field trials depended on local settings. To overcome this, 
an evaluation programme on RDTs was established in 2006, called the WHO Malaria RDT Product 
Testing Programme. The results were presented in a report, helping to guide countries when 
selecting RDTs and thereby improving quality of the RDTs (124). 
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During RDT testing, this programme evaluates how often the tests show correct results, either 
positive or negative, as well as how often the tests were regarded as invalid (124). The usability and 
robustness of the tests were also assessed, including how stable their performance was under 
different temperatures. The tests are evaluated by using a panel detection score (PDS), which is the 
percentage of tests that are positive when blood with parasite density of 200 or 2000 parasites/μl 
are tested in laboratory settings. WHO uses PDS because the results only depend on the intrinsic test 
traits, while sensitivity and specificity are tested in clinical settings with errors connected to this 
(125).  
In areas with high transmission intensity, the threshold for clinical disease is normally above 200 
parasites per microlitre, which is the lower density limit tested in this programme. The test sensitivity 
depends on parasite density (124). The symptomatic threshold of parasite density depends on 
acquired immunity, and will therefore for most part correlate with transmission intensity as well (11). 
As described earlier, vulnerable individuals, such as pregnant women and HIV infected, have lower 
threshold density even in high endemic areas. 
Several criteria should be met before the RDT can be recommended by the WHO: the PDS should be 
above 75% in samples with 200 parasites/µl, with less than 10% false positives and less than 5% 
invalid results (123). In addition, the usefulness of RDTs does not solely depend on their intrinsic 
qualities that are revealed in a laboratory setting, but also on several external factors, such as their 
stability during transport and storage, their usability and cost (123). 
5.8.2 Recommendations in treatment 
The increasing antimalarial drug resistance over the last decades has prompted sweeping changes in 
the malaria treatment guidelines stipulated by the WHO. Modern malaria treatment is largely based 
on the use of ACTs instead of monotherapies. As previously stated, the reason for this is twofold. 
First, ACTs are generally more effective than the available monotherapies; second, using two drugs 
with different modes of action slows development of resistance. Five ACTs are currently 








5.8.2.1 Guidelines for treating uncomplicated malaria 
Current malaria treatment guidelines recommend using ACTs for the treatment of uncomplicated 
malaria; the five recommended ACTs are regarded as equally valid, though local resistance 
tolerability patterns have to be assessed in order to select the right ACT for the region. Other 
considerations include the availability and cost of fixed-dose combinations, which simplifies 
treatment and increases compliance (2). 
The guidelines further stipulate that treatment should be given for at least three consecutive days, in 
order to ensure that artemisinin kills off over 90% of the parasites. Research shows a clear increase in 
28-day treatment failure rates for shorter durations. By having the artemisinin take care of the 
majority of the parasites, the partner drugs will be exposed to fewer parasites, thus reducing the risk 
of developing resistance even further (2). 
In the case of treatment failures, emphasis is placed on having a second-line treatment available. 
Ideally, the second-line treatment should be an alternative ACT known to be effective in the area; if 
this is not possible, a longer 7-day treatment course of either artesunate or quinine should be given 
in combination with either tetracycline, doxycycline or clindamycin (2). 
5.8.2.2 Guidelines for treating complicated malaria 
When it comes to treating complicated malaria, the guidelines recommend prompt intravenous 
treatment with artesunate for both children and adults. This is preferred over quinine for several 
reasons, but mainly because of studies showing artesunate significantly reducing risk of death 
compared to quinine. Other factors such as not requiring rate-controlled infusions and better 
tolerability also contribute to the recommendation of artesunate over quinine. If parenteral 
artesunate is unavailable, either artemether or quinine is regarded as acceptable alternatives (2).  
In addition to the prompt treatment with artesunate or suitable alternatives, the treatment 
guidelines recommend various adjunctive treatments for certain complications of malaria, 
attempting to reduce the high mortality of severe malaria (2).  
5.8.2.3 Guidelines for treating special patient populations 
Pregnant women are a high-risk group for developing severe malaria, and emphasis is placed on 
giving these patients prompt treatment if they develop symptoms of acute malaria. However, there 
is still a lack of information on the safety and efficacy of many antimalarial drugs when used in 
pregnancy, including ACTs (2). 
In the first trimester, pregnant women with symptoms of uncomplicated malaria should ideally be 
treated with quinine plus clindamycin for seven days; if clindamycin is unavailable, quinine 
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monotherapy is recommended. Second-line treatment for pregnant women is artesunate plus 
clindamycin (2). 
As some women in the first trimester may not be aware that they are pregnant, asking about the 
possibility should always be done before starting treatment. Small-scale studies indicate that 
artemisinin derivatives are adequately safe for use in the first trimester, but more research is needed 
before this can be incorporated into treatment guidelines (2). 
For the second and third trimesters, use of artemisinin derivatives has been shown to be reasonably 
safe, and uncomplicated malaria in these women can be treated with ACTs. DP is the only exception, 
as there is still insufficient information to use as first-line treatment for pregnant women. If ACTs are 
unavailable, a seven-day course of artesunate plus clindamycin is indicated (2). 
Pregnant women with complicated malaria have a significantly higher mortality, approximately 50%, 
compared to non-pregnant women. Prompt treatment is therefore the highest priority. In the first 
trimester, both parenteral quinine and parenteral artesunate are valid options for treatment, even 
though there are uncertainties over the safety of the artemisinin derivatives. In the second and third 
trimesters, parenteral artesunate is preferred over quinine, as quinine has been shown to increase 
risk of hypoglycaemia in pregnant women (2). 
Lactating women should follow the general guidelines. None of the drugs currently recommended as 
first-line treatment appear to be present in the breast milk in large amounts, and it is unlikely that 
using the current first-line drugs is harmful for infants. Breastfeeding women should however avoid 
tetracycline and primaquine (2). 
For infants and young children, the general guidelines should also be followed, as artemisinin 
derivatives have been shown to be safe and well tolerated by children. However, special care has to 
be taken in order to administer accurate dosing, which may be difficult, especially if paediatric 
formulations are unavailable (2). 
5.8.2.4 Guidelines for limiting antimalarial resistance 
In order to monitor the resistance to antimalarial drugs worldwide effectively, malaria-endemic 
countries are encouraged by WHO to assess the malarial resistance for the first-line treatment and 
second-line treatments, as well as other applicable drugs, at regular intervals, ideally at least once 
every two years (46). 
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To ensure adequate treatment efficacy and to limit developing further development of resistance, 
WHO recommends that treatment policy changes should be initiated when any of the currently used 
treatment options have treatment failure rates exceeding 10% (46). 
5.8.3 Recommendations for malaria prevention 
Malaria prevention is mainly based on malaria vector control and chemoprevention (3). The former 
consists of ITN utilization, IRS and larval control (3), of which the first two is more common because 
of their efficacy under several different circumstances and imperfect coverage (82). 
Chemoprevention is recommended to pregnant women and infants in high transmission areas, as 
well as to children in seasonal transmission areas (126). 
5.8.3.1 Guidelines for using insecticide treated nets 
WHO state that the long lasting option is preferable, which means that the nets distributed by 
campaigns following the WHO guidelines are LLINs (3). Large campaigns are also recommended to 
survey the net duration at selected sites, to assess the need for new distribution as the duration may 
vary. This may also enable campaigns to choose the products best suited for local settings (65). There 
is also a kit for re-treating other nets with long-lasting insecticide. WHO’s goal is to have full coverage 
of long-lasting ITNs, with one net for every second person. When this is not achieved, pregnant 
women and children below five years of age should be prioritized (3). 
5.8.3.2 Guidelines for using indoor residual spraying 
The guidelines regarding IRS are detailed, both when it comes to requirements and 
recommendations. WHO recommends utilization of IRS as a vector control method in countries 
where knowledge of local vector traits indicates that this intervention is cost-effective. Vector traits 
include local resistance towards insecticides, which should be evaluated and monitored before and 
during implementation of IRS. In addition to thoroughly selecting areas for intervention, the 
insecticide should be carefully selected and the execution should be well planned (80). 
Transmission intensity and the other implemented intervention methods in the area should also be 
considered. The guidelines do not give any strict rules regarding which settings IRS can be 
implemented in, but state that spraying in densely populated areas and as well as in areas where 
malaria has a seasonal pattern may give higher efficacy. The latter may also result in the need of 
fewer rounds of IRS, as one round should ideally last six months (81). The degree of coverage of LLINs 
should affect the choice of insecticide, as described in more detail below (82).  
Combining IRS with ITNs should currently only be done in specific settings. Using non-pyrethroid-
based IRS in areas with pyrethroid resistance and high LLIN coverage may help reducing the selection 
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pressure and slow resistance development. Combining the two measures can also be done in 
transitional periods when changing intervention methods, in addition to increasing the effect of 
existing interventions (81). 
The insecticide indicated in an area also depends on the housing material (81), an important aspect 
since the overall efficacy depends on the ability to spray at least 80% of the buildings in the area. It 
also is important to maintain insecticide susceptibility, and therefore avoid inadequate or inaccurate 
usage (80). Methods to maintain susceptibility will be further discussed below. 
The WHO guidelines state that all peripheral aspects regarding IRS should be established before 
implementing the measure. This includes the training of staff, solving logistical challenges, and 
having the resources and equipment for insecticide handling ready. WHO has also developed 
recommendations for the spraying equipment and its maintenance. Strides should be taken to avoid 
excess contamination of the surrounding areas to minimize environmental and human exposure, 
which include managing waste (81). 
The insecticides recommended by the WHO Pesticide Evaluation Scheme (WHOPES) are considered 
to be safe to humans and to the environment when used as recommended (81). Adherence to the 
IRS guidelines is therefore important to minimize potential hazards. Following safety measures 
during spraying, such as removing food and covering furniture may reduce unnecessary exposure in 
the population. For the spray operators, safety equipment should be used and routine health 
controls may be indicated depending on the insecticide used. WHO also emphasize the importance 
of trained staff, including spray operators and technicians (81). 
Malaria vector control through IRS depends on collaboration from the population at risk. To ensure 
their informed consent, WHO recommends strategies for public information, including developing 
so-called information, education and communication (IEC) strategies and to conduct IEC campaigns 
before the start of each spray round. Addressing local leaders may help in the community acceptance 
to the intervention as well (81). 
As many countries may have difficulties with adherence of these recommendations because of 
limited resources, WHO states that they will help countries in challenges related to local research 
and administration of this intervention. In addition, WHO aims to increase research and progress on 
IRS related topics (80). In return, WHO requires reports on usage details, as well as effect and 
resistance when available (81). 
5.8.3.3 Guidelines for managing insecticide resistance 
The keyword in this topic is prevention. WHO recommends six tactics in total to reduce development 
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of resistance, as this is more effective beforehand. First, in areas intending to use insecticides for 
vector control, there should be a focus on resistance from the beginning, and the methods that have 
the least impact on resistance should be chosen. Secondly, the planning should aim for the most 
effective usage of the measure itself, both to reduce the costs and to avoid vector exposure in 
suboptimal dosages, which might cause selective pressure. Thirdly, methods combining exposure of 
different insecticides should be considered, such as changing the insecticide used in IRS between 
different years, avoiding IRS with pyrethroids in areas with LLINs, and preferably, using products 
combining different insecticides (82).  
The fourth tactic focuses on monitoring, emphasizing the need for continuously observing and 
evaluating the resistance in areas of insecticide use. Fifth, WHO also stress the need for progress in 
vector control, both in finding alternative methods and new insecticides. As pyrethroids are still the 
only insecticides used to treat LLINs, finding new options is especially pressing. The sixth and final 
tactic is prioritizing short-term investments in order to make the measure viable in the long-term. An 
example on such short-term cost would be choosing a different insecticide for IRS than pyrethroid 
when used in combination with LLINs, and in that way avoiding increased selection pressure (82). 
The distribution of LLINs has increased rapidly over the last decade, but the increasing pyrethroid 
resistance may jeopardize their efficacy. Pyrethroids are currently the only insecticide group 
recommended for treating the bed nets. Nevertheless, even if extensive pyrethroid resistance 
develops, the bed nets will still be able to give some protection against malaria infection, in much the 
same way as untreated nets. With a reduced effect of the insecticide, there is an increased 
importance of having an undamaged net, however (81). 
The six tactics to reduce evolution of resistance mentioned above should be followed in areas that 
are implementing IRS, especially when using pyrethroids. This insecticide can still be used in some 
areas, but should be avoided in areas of extensive ITN usage, since the recommended nets are 
impregnated with the same insecticides (81). 
There should be a thorough surveillance of resistance, and actions should be taken as a result of the 
current resistance situation. One method for monitoring resistance is by using bioassays, through 
which the susceptibility to the insecticide can be estimated. If less than 80% of the mosquitoes die, 
WHO recommends changing insecticide; if more than 80% die, the situation should continue to be 
monitored and assessed, but usage of the current insecticide can continue (81). 
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The WHOPES focuses on the pesticide use and safety, including research of new options and 
monitoring the global use (127). As resistance limits the number of efficient alternatives, WHOPES 
promotes development of new insecticides for public health use (128). 
5.8.3.4 Guidelines for larviciding 
The WHO guidelines regarding larviciding in sub-Saharan Africa specify that the use should be 
thorough and according to local knowledge and features, and preferably only in areas with a few, 
known and semi-permanent breeding sites. This intervention is described to chiefly be an addition to 
other vector control methods, such as ITNs or IRS. This recommendation is based on the estimation 
of IRS and/or ITNs as more cost-effective in most settings. Urban areas with seasonal transmission 
are the most likely to benefit from larviciding (85). 
5.8.3.5 Guidelines for intermittent preventive treatment in pregnancy 
WHO have recommended IPTp consisting of two courses of SP to pregnant women in malaria 
endemic areas since 2004. The courses should have at least one month between them, with the first 
in the second trimester and the following course within the last month of pregnancy. To HIV-positive 
women, three courses are recommended (34). In this group of women, it is also important that co-
trimoxazole and SP should not be administered simultaneously (89). 
The WHO recommendation for using SP in IPTp has been adopted as national policy in 31 of 37 
endemic countries in Africa, with the remaining countries using more frequent IPTp (129). Several 
trials have focused on effect of increased frequency, especially in areas with extensive resistance. 
However, the results are inconsistent. McClure et al. found a decreased risk of LBW among women 
receiving more than two doses of SP in several of the studies they reviewed (91). Diakite et al. found 
lower LBW rates among those who received three doses compared to those receiving two doses of 
SP (130). 
A recent review of seven trials found lower risk for LBW if the women received more than two doses 
of SP as IPTp, even in areas with high resistance. They also found a significant decrease in preterm 
births among the women receiving more frequent administration of SP. In these seven trials, there 
were no signs of association between increased frequency of SP and the risk of neonatal kernicterus 
(129).  
Kuile et al. did not find significant difference between two doses and monthly SP in HIV-negative 
women, even in areas of resistance up to 24%. In Malawi, however, where the resistance was 39%, 
the monthly regime showed significant reduction in peripheral parasitaemia. In their analysis on the 
effect of IPT on paucigravidae given two doses of SP, Kuile et al. found significant protection against 
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maternal anaemia, LBW, and placental malaria, compared to controls in an area of resistance 
between 19 and 26% (131). Paucigravidae with HIV infection, however, were found to have a 
statistically significant lower risk of placental malaria when receiving monthly SP instead of two doses 
of SP as IPTp (131). This suggests that even with inconclusive results, implementing IPTp with 
increased frequency in national guidelines may be justified. 
5.8.3.6 Guidelines for intermittent preventive treatments for infants 
WHO recommends to give IPT with SP to infants in areas where malaria transmission is moderate or 
high and where the prevalence of the pfdhps mutation is below 50%. They suggest the treatment to 
be coordinated with the vaccine program (3). This recommendation from March 2010 has as of 2012 
yet to be implemented in any national guidelines (92). The requirement of measuring resistance 
prevalence using molecular markers may be one reason for this lack of response, as this information 
is not available at regional level in several endemic countries. Increased levels of molecular markers 
are associated with increased treatment failure. However, this association is weaker for prophylaxis 
and trials have shown significant efficacy of IPTi in areas of moderate treatment failure (92). 
5.8.3.7 Guidelines for seasonal malaria chemoprevention 
In 2012, WHO implemented seasonal malarial chemoprevention into their recommendations. This 
may be given to children between 3 and 59 months of age in highly seasonal areas in the sub-Sahel 
region, and is based on monthly administration of the combination of amodiaquine plus sulfadoxine–
pyrimethamine during transmission season. As with other chemopreventive methods, this should not 
be given to children receiving co-trimoxazole. An additional requirement is that the efficacy of the 
drug combination should be above 90% (126). 
5.8.4 Recommendations in the use of DDT 
During the latter half of the 20th century, the potential effects of DDT on human health as well as on 
the environment led to increasing scrutiny and scepticism, and the chemical became banned in the 
USA in 1972. The Stockholm Convention on Persistent Organic Pollutants classified DDT as a 
persistent organic pollutant, in addition to 11 other chemicals, severely restricting their production 
and use. When it comes to DDT, all use is banned, with the exception of indoor application as a 
measure against vector-borne diseases; this exemption is in effect until better insecticide alternatives 
are developed. WHO has evaluated the findings of the Stockholm Convention, and applied their 
recommendations in their own guidelines. DDT has the longest insecticidal duration when used in 
IRS, resulting in fewer required spray cycles in order to achieve optimal effect, making it a more 
realistic alternative for IRS than most other insecticides. Because of this, DDT is still recommended by 
the WHO as a measure to control malaria in certain circumstances (132). 
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WHO monitors any new information regarding the safety of DDT continuously. In 2000, an 
assessment into the current information on the safety of DDT was performed; it was found that, 
though extensive research had shown toxic effects in laboratory animals, the current levels of 
exposure in humans were generally within safe limits. DDT was therefore regarded as safe in its use 
as a vector control measure, as long as the guidelines for its safe application and use were strictly 
followed. 
DDT is currently only recommended for use in IRS in areas where there are susceptible vectors. 
Therefore, before DDT can be introduced as a measure to control malaria in an area, local insecticide 
resistance has to be assessed. Because of widespread resistance towards organochlorines such as 
DDT, many countries started using pyrethroids instead; this may lead to pyrethroid resistance, which 
not only affects the efficacy of IRS, but also the LLINs, which are pyrethroid treated as well (132). An 
example of this was seen in South Africa, where DDT had to be reintroduced shortly after 
discontinuation because of the appearance of pyrethroid-resistant An. funestus vectors (133). 
In order to avoid unnecessary exposure in workers and in the population, DDT application and 
storage should follow national guidelines as well as recommendations outlined in the WHO technical 
guidance documents and in the Stockholm Convention (132). 
In order to monitor the current usage of DDT in IRS, any use of DDT must be reported to both WHO 
and the Secretariat of the Stockholm Convention. These institutions will evaluate the current use in 
terms of benefits and safety, and take into account information about local resistance patterns, as 
well as alternative measures that can be utilized to control malaria in the area; the effect of these 
evaluations is to limit the unnecessary use of DDT (132). 
Progress in developing alternative insecticides and vector control strategies in the last decades has 
been insufficient; until suitable alternatives are found, WHO concludes that there still is indication for 
using DDT in some areas (132). 
5.9 Malawi 
In order to gain better understanding of what kinds of challenges Malawi faces when it comes to 
malaria, we will first introduce some facts about the country and its health care system. In addition, 
we will examine the role of WHO in the context of improving the health in Malawi. After this, we will 
give an outline on the current malaria situation in Malawi, including Malawi’s national guidelines for 
diagnosing, treating and preventing malaria. Finally, we will give a quick overview of some of the 




5.9.1 About Malawi 
Malawi is a completely landlocked country in sub-Saharan Africa, with borders to Mozambique, 
Tanzania and Zambia. Malawi’s eastern border is dominated by the 475 kilometre long Lake Malawi 
(134), which accounts for about one fifth of the total area of the country (135). The Rift Valley runs 
through the country (134), creating a diverse geographical landscape with high plateaus in the north 
and central areas, and fertile lands surrounded by large mountain peaks west and south in the 
country (134, 135). The country has two seasons, a cold-dry season from April to November, and a 
hot-wet season from November to April (135). 
 
Figure 3: Lake Malawi is a defining feature in Malawi's geography and culture. Cape Maclear, Malawi; 
picture taken by authors. 
Malawi is an agricultural country; comprising nearly one-third of the gross domestic product, 
agriculture also accounts for the vast majority of the domestic exports (134). Tobacco is Malawi’s 
most important export, but significant amounts of tea and sugar are also exported (135).  
In the 2008 census, Malawi had a population of 13,077,160 people, with an average growth rate of 
2.8% per year between 1998 and 2008. Almost 85% of the population was classified as rural, and 67% 
were under age 25 (134).  
5.9.2 Health and development challenges in Malawi 
The health care system in Malawi is divided into three levels: primary, secondary and tertiary care. 
Primary care is provided on the community level, mainly through health centres or small community 
hospitals. Secondary care is provided by larger district hospitals, of which there are 56 in total in 
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Malawi. Finally, tertiary care is provided through five central hospitals throughout the country. In 
addition to this, there is a wide network of charity-driven or privately-owned health care facilities 
throughout Malawi, mainly providing primary and secondary care (136). 
 
Figure 4: Zomba Central Hospital, one of Malawi’s five central hospitals. Picture taken by authors. 
Malawi is facing a big challenge dealing with a growing burden of communicable diseases like 
HIV/AIDS, malaria and tuberculosis. Malaria is responsible for about 40% of hospitalizations of 
children under five, as well as 40% of total hospital deaths. The national prevalence of HIV was 
estimated at 12% in adults in 2007 (136). In addition to these well-known diseases, several neglected 
tropical diseases are probably on the return, even though the true extent of this is still unknown. 
Malawi also have a significant burden of non-communicable diseases like cancer, and these diseases 
contribute significantly to both the overall mortality in Malawi, as well as the public health 
expenditure (136).  
The human resources situation in Malawi is also a challenge; a survey from 2006 revealed that 
Malawi had the lowest ratio of health care workers in the region, with 2 physicians and 59 nurses per 
100,000 people. This problem appears to be twofold. The output of training institutions is not only 
too low to satisfy the demand for health care workers, those that are trained often go on to work in 
the private sector or outside of the country. Efforts have been made to increase the training output, 
in the hopes that this may alleviate the human resource shortages over time (136). 
Additionally, there are several other factors that may affect public health. In 2010, over 90% of 
households lacked electricity or access to improved sanitation, and about 20% did not have access to 
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an improved water source (134). These factors represent other significant public health challenges in 
Malawi. 
5.9.2.1 Maternal health 
The fertility rate in Malawi is strongly correlated with the women’s education level; in 2010, it ranged 
from 6.9 in women with no education, to 2.1 in women with more than secondary education (134). 
Malawi has a high maternal mortality ratio, which in 2008 was at 807 per 100,000 live births; there 
may be several reasons for this, including for instance that only half of the pregnant women receive 
the recommended IPTp regimen, and that only half of the deliveries are performed by trained health 
care workers (136).  
5.9.2.2 Child health 
While neonatal mortality has remained mostly the same since 1985, the mortality rates for infants 
and children under-five have fallen. Part of this may be because of an increased focus on 
immunization during childhood, which has effectively eliminated measles and neonatal tetanus, as 
well as significantly reducing polio (136). 
Malaria, pneumonia, diarrhoea and HIV/AIDS were the main contributors to childhood morbidity and 
mortality in 2005. Malnutrition in children is still a significant problem in Malawi (136), and there is 
still a large potential for reducing the burden of malaria by focusing on preventive methods in 
children; in 2010, only 40% of children under five were sleeping under ITNs, even though over 55% of 
households had at least one ITN available (134). 
5.9.3 WHO in Malawi 
As stated earlier, WHO is working closely with governments around the world to improve global 
health. This includes cooperation with Malawi. The WHO Malawi Country Office works with the 
Malawian government and other relevant partners in order to promote public health in Malawi 
(137). 
5.9.3.1 Country Cooperation Strategy  
The Country Cooperation Strategy (CCS) is a document provided by the WHO Regional Office. It 
identifies challenges and needs in the health care system, and gives support in developing the 
national health plan (136). The CCS focuses on increasing the national health security, strengthening 
the health care system, and reducing poverty and inequality while at the same time investing in 
health (136).  
The first generation CCS was in effect in 2005–2007 and focused on supplying strategies for 
cooperation between the national government and relevant partners in an effort to strengthen the 
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health care. The second generation CCS came into effect in 2008, and is valid through 2013, and 
focuses on weaknesses in the public health system that were uncovered during the first CCS (136). 
In 2007, Malawi changed the first-line treatment in their national treatment guidelines from SP 
monotherapy to ACTs. WHO gave the government strategic and financial support during this change. 
In addition, several measures were taken in order to strengthen reproductive health, mainly by 
strengthening the maternal health care service and developing national guidelines for maternal care 
during the time the first generation CCS was in effect (136). 
The second generation CCS has three priority areas. The first is enhancing the health security, both 
on an individual and national level. Second is an overall strengthening of the health system in 
Malawi. The third area is to reduce the health burden of poverty by investing in health and 
counteracting causes of poverty.  
When it comes to the first priority area, enhancing the health security, several approaches are taken. 
The first CCS revealed that the handling of epidemics and natural disasters was a significant 
weakness in Malawi, and measures are taken to increase readiness for such events. In addition to 
this, work continues with reducing the burden of both communicable and non-communicable 
diseases, as well as reducing the maternal and childhood mortality rate further. This is done by 
supporting various preventive measures in the population as well as strengthening the systems for 
monitoring, preventing and handling disease in vulnerable patient populations (136). 
Strengthening of the health system is another challenge, as resources are limited and priorities have 
to be made in order to utilize them to the fullest. The central aspect to this is to increase the overall 
capacity in the health care system, as well as promoting evidence-based medicine (136).  
The third priority is investing in health and reducing the health burden of poverty. This is approached 
by, amongst other things, involving the communities in the planning and implementing health 
improvement measures; by getting the civil populations directly involved in health care matters, it is 
hoped that some of the inequity in the current system will be counteracted (136).  
5.9.4 Malaria in Malawi and the national guidelines 
P. falciparum is the major Plasmodium species, and the most common Anopheles species are An. 
gambiae, An. funestus and An. arabiensis (138). Vector resistance against the pyrethroids and DDT 
was demonstrated in 2009. Malawi has high transmission of malaria, and 95% of the country is 
endemic. The transmission is perennial in most areas, but with seasonal variation (1). Transmission 




6.7 million malaria cases were reported in 2010 (1), but the real incidence is uncertain as few cases 
are reported (139). Reported cases of malaria, regardless of diagnostic method, increased from 2005 
to 2010; this increase is possibly due to improved reporting, and does not necessarily represent a 
real increase in malaria cases in this period (1). Malaria is an important cause of morbidity and 
mortality in Malawi; 40% of hospitalizations in under-fives and 40% of the overall mortality in 
hospitals is caused by malaria. The disease also causes morbidity indirectly through the economical 
strain it places on the population. In very poor households, 30% of the budget is spent on malaria (1). 
There are several challenges when it comes to diagnosis and treatment. The guidelines in Malawi 
recommend parasitological diagnosis, but this may be difficult to carry out consistently. Microscopic 
diagnosis is only available to all patients at 25% of the health facilities due to a shortage of trained 
technicians and laboratory supplies, as well as unstable electrical supply. Scaling up RDTs for use in 
confirming malaria diagnosis has been on-going since 2011, but there have been problems with 
shortages here as well (1). 
Malawi has been a pioneer in changing the drug for first-line treatment of malaria according to 
increase in resistance. They were first in sub-Saharan Africa to change from chloroquine in 1993, and 
again to change from SP in 2007. The national guidelines now stipulate that artemether–
lumefantrine should be used as the first line treatment for malaria infection. The drug for second line 
treatment is artesunate–amodiaquine, while quinine intravenously is still recommended for severe 
malaria. First line treatment is free of charge when indicated (1). In addition, the national guidelines 
stipulate rapid treatment for suspected malaria illness, preferable less than 24 hours after symptoms 
start (140). 
The proportion of children under five years of age receiving the recommended treatment for their 
febrile illness within this time frame is still just 25%. In areas that are hard to reach, antimalarial 
treatment may be given by local health surveillance assistants to increase availability of treatment 
within the recommended time (1). The ratio of children with fever in the previous two weeks who 
received an appropriate antimalarial drug has increased slightly, from 24% in 2004 to 28% in 2010 
(139). 
In public health care facilities, children are treated according to the new guidelines from 2007. 
However, full adherence is not achieved at community level or in the private health facilities. Second 
line treatment is rarely administered in situations where parasitological diagnosis can be attained 
(139). Challenges facing malaria treatment include reported stock-outs of drugs and higher utilization 
of ACTs compared to confirmed reported malaria cases, indicating possible overtreatment. Training 
health personnel in the new guidelines and improving the diagnostic services may improve 
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adherence to treatment guidelines (139). 
Malawi’s first national ITN programme was established 
in 2003, and distribution is now divided between giving 
out free LLINs at antenatal care (ANC) and immunization 
clinics (see Figure 5), large distribution campaigns, as 
well as private purchase through commercial outlets (1). 
However, stock-outs of ITNs have been reported in some 
facilities, and some reports suggest that there is misuse 
of ITNs in the population as well (139). Today, all 
Malawians are recommended to sleep under a bed net, 
preferably a LLIN, in contrast to the earlier 
recommendation of use only among children under five 
years of age and pregnant women (1). 
A report from 2010 found that ownership of ITNs and 
utilization among pregnant women had risen from under 
10% in 2002 to 60% in 2010, and that utilization among 
children under five had increased from 8% to 54% over 
the same time period (139). 
The majority of children under five years of age in households with an ITN slept under the bed net 
(80.7%), with an even higher percentage among children under three years of age (140).In addition, 
IRS has been recommended since 2007, though without including utilization of DDT in the guidelines 
(138). IRS has already been applied in one district for some time, and has recently been rolled out to 
include another six districts (1, 139). 
Malawi has implemented IPTp and bed net distribution in their antenatal care programme. Prompt 
treatment for clinical episodes of malaria is also given in ANC. There have been reports that quinine 
and SP has been administrated to uncomplicated cases in pregnant women (139). In 1993, Malawi 
implemented IPT with two doses of SP during pregnancy in their national guidelines, as the first 
country in Africa and nine years before WHO recommended it in their guidelines. The IPTp guidelines 
were modified in 2002 to include recommendations from WHO regarding HIV-infected pregnant 
women, and now stipulates that women should be given at least two doses of SP during pregnancy. 
This preventive treatment should be given under observation and free of charge at ANC clinics (1). 
In Malawi, 90% of women visit antenatal care clinics at least once during their pregnancy. The 
Figure 5: Bed nets ready for distribution 
to pregnant women. Zomba Central 




coverage of IPTp is lower; while 76% received SP at least once during pregnancy, only one in two 
pregnant women received the recommended IPTp regimen of at least two doses. Nevertheless, this 
is almost two times as many as in 2000. The country report from RBM indicates that this gap 
between attendance at ANC and coverage of IPTp may result from imprecise guidelines on when IPT 
should be given, shortages of equipment or shortage of the drug itself, in addition to personal 
concerns about the safety and efficacy of the drug (1). 
The National Malaria Control Programme (NMCP) develops a National Malaria Strategic Plan that 
emphasises on important challenges within the recommended interventions, in addition to asserting 
goals for a five year period (140). A programme review from 2010 noted the impact of the 
interventions, and addressed the challenges limiting improvement (139). As the goals for 2010 were 
not achieved, they were asserted into the aim for 2015.  
The National Malaria Strategic Plan states that interventions should strive to increase ITN utilization 
among pregnant women and children under 5 to 80% within 2015. They also hope to achieve at least 
one ITN in 9 out of 10 households. In addition to this personal vector control, they hope to 
implement IRS in 12 districts with high malaria burden. The goal for coverage of the recommended 
regimen of IPTp is 80%. When it comes to diagnostics, they hope to have confirmed diagnosis in 80% 
with RDTs and in 50% by microscopy in the future. For treatment, the target is to treat malaria cases 
with the recommended drug within 24 hours in half the cases (1). 
In addition to scarcity of resources, community attitudes can be a challenge in reaching the 
intervention goals. For example, treatment within 24 hours after onset of symptoms may be difficult 
if the parents postpone seeking treatment. Education and health information may diminish 
misconceptions regarding the interventions, and in this way improve attendance. NMCP therefore 
proposes further expansion of public information strategies, preferably in collaboration with the local 
malaria coordinator (139). 
The NMCP also encourages surveillance of malaria statistics, which can be used for decision-making 
later. This surveillance has demonstrated that few malaria cases were confirmed before treatment in 
general; for the central hospitals, only 25% were confirmed before 2010. NMCP urge for increased 
collaboration between research community and surveillance teams, so the research can be better 
adapted to the current needs. To maintain the improvements achieved over the last decade, the 
NMCP addresses the need for increasing human resources, in addition to continued efforts to scale 
up the existing interventions. Changes in the malaria strategic plan should be based on evidence, and 
continued monitoring is therefore also important (139). 
 
58 
5.9.5 On-going malaria research in Malawi 
There is a lot of on-going current malaria research in Malawi. An outline of some of the projects is 
given here; the challenges related to later in this paper. These projects are based either partly or fully 
in Zomba in Malawi, and are supervised by Dr Kamija Phiri of Malawi’s College of Medicine. 
 
Figure 6: A nurse working in research at Zomba Central Hospital, Malawi. Picture taken by authors. 
 
5.9.5.1 Pfizer study: Finding new alternatives for IPTp 
The Pfizer study is an open-label study, comparing different IPTp regimes. The study looks at the 
efficacy of the combination azithromycin plus chloroquine (AzCq), compared to sulfadoxine–
pyrimethamine (SP), which is the current first-line drug for use as IPTp. 
The study is an international collaboration, with fieldwork in Malawi, Tanzania, Kenya, Uganda and 
Benin. Pregnant women between 14 and 26 weeks of gestation are randomized to receive either SP 
or AzCq as IPTp. Exclusion criteria include symptoms of active malaria disease and taking IPTp or 
other antimalarials in the last four weeks. 
The women were given three courses, with 4–8 weeks between each course (depending on 
gestational age in enrolment). They were followed with routine screening for sexually transmitted 
diseases, urine dipsticks, and haemoglobin during pregnancy, tested for placental malaria at delivery 
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and were followed up 28 days after birth. In addition, several of the participants were tested with 
nasopharyngeal swabs for monitoring any resistance of S. pneumoniae.  
5.9.5.2 Pfizer sub study: Testing efficacy of novel drug combination for use as IPTp 
The second trial also concerned the use of a drug combination of azithromycin and chloroquine 
during pregnancy. Asymptomatic paucigravidae with parasitaemia at enrolment were given 
treatment with AzCq and followed weekly with estimating haemoglobin level and malaria parasite 
count for the next 42 days. The tablets were given with food, and administration was observed. 
5.9.5.3 MALARID: The role of iron supplementation after malaria 
The MALARID study is trying to assess whether iron supplement should be given to children treated 
for malaria, and if so, what the ideal time of the prospective iron supplementation is. Children 
between 4 and 30 months that tested positive for malaria on a rapid diagnostic test were treated 
according to national guidelines. Participants were asked to come back three days after starting the 
treatment to confirm that they are malaria free. They were then randomized into three groups: one 
group receiving iron supplement immediately (that is, right after ending the malaria treatment); the 
second group received iron supplements two weeks later, and the third group received a placebo. 
Children with treatment failure or severe anaemia were evaluated further for proper treatment; they 
were therefore not included in the study. Enrolled children were followed up every two weeks the 
next three months. In these follow up sessions, their guardians were asked about several factors, 
including any adverse health symptoms, sickness in the family, usage of bed nets, and more. In 





Figure 7: Measuring Hb in children as part of the MALARID study. Zomba Central Hospital, Malawi; 
picture taken by the authors. 
 
5.9.5.4 MaRCH: Malaria rebound following co-trimoxazole prophylaxis in children 
In the MaRCH study, malaria prevalence was assessed in three groups of children: children with HIV 
negative mothers (controls), children with HIV positive mothers with a negative PCR test for HIV at 6 
weeks of age (unexposed cases), and children with HIV positive mothers who have a positive PCR test 
for HIV at 6 weeks of age (exposed cases). The overarching goal of the study is to assess whether 
there is a rebound effect, i.e. an increased malaria incidence, following the discontinuation of 
prophylactic use of co-trimoxazole in children.  
The exposed children were followed up every two months with measurement of weight, height, mid-
upper arm circumference, vital signs (if needed), and lab tests every second month. Two 
independent technicians estimated the parasite density, both unaware about the children’s exposure 
status. In addition to the measurements, the mothers were asked questions about the use of bet 
nets, compliance of medicine for the exposed, health of child since last visit, and so on. On these 
visits, the medication for the next two months is given. In addition to the planned visits, they were 
asked to come in if the child got ill during this trial. The unexposed children were followed up in the 
field, with the same measurements and questions.  
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5.9.5.5 MIH: The effect of co-trimoxazole on immunity against malaria 
The last study we were in contact with hopes to assess the effect of co-trimoxazole on developing 
immunity against malaria. This study uses the same case and control groups as the MaRCH study 
detailed above. The children from HIV infected mothers are tested for HIV at six weeks and then 
again at twelve months of age. All of the children are given co-trimoxazole the first twelve months. If 
they test positive at 12 months, they are started on antiviral medications. If they test negative, the 
mothers are encouraged to stop breastfeeding, and the test is retaken after six weeks. If this test is 
negative as well, the co-trimoxazole is discontinued. Follow ups were conducted regularly, and 




There are still substantial challenges facing sub-Saharan Africa in regards to malaria. While many 
countries outside of sub-Saharan Africa have achieved a partial or complete eradication of malaria, 
the disease continues to be a heavy burden for sub-Saharan countries (63). 
It is telling that the mortality of malaria is so low in the Western world when the burden of the 
disease is so vast in most malaria endemic countries; with the right resources, almost all malaria 
deaths are preventable deaths (63). What can be done to improve the situation in sub-Saharan Africa 
and particularly in Malawi? 
In this chapter, we are going to discuss the different challenges that Malawi are facing when it comes 
to fighting malaria, and why it can be difficult for Malawi to implement some of the international 
guidelines described earlier. In addition, we will discuss the relevance of the guidelines themselves, 
and how both local and international research can contribute to changing the guidelines and make 
better guidelines for the future. Finally, we will discuss the role of DDT today, and some of the 
challenges regarding its use in the future.  
6.1 Health care challenges in Malawi 
Malawi has come a long way in the fight against malaria. However, to combat this disease effectively, 
several problem areas have yet to be covered sufficiently. Malawi faces several challenges that make 
an optimal approach to these problem areas difficult (140). In this chapter, we will take a closer look 
at what makes fighting malaria in Malawi difficult. 
6.1.1 The lack of human resources 
Strengthening the health care system has long been a prioritized area in Malawi, as seen by the focus 
in both past and current Country Cooperation Strategies; the training of qualified and skilled workers 
is central to this effort. In addition, there is a need to improve and strengthen the structure of the 
health care system in the districts, and to improve the coordination and communication of all the 
different partners involved in the malaria control in Malawi (136). We feel that this is one of the most 
important areas to focus on for the future, if the fight against malaria should continue to gain 
momentum. 
One of the major challenges in the continued fight against malaria in Malawi is the human resources 
situation. More personnel are needed on a national, regional, district and community level in order 
to further roll back malaria, and to provide satisfactory care for the affected patients. The reason for 
this is twofold: first, there are too few people educated each year to meet the demand, and second, 
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the skilled workers who get educated often tend to seek more lucrative jobs, either in the private 
market or out of the country (136). 
This corresponds with what we experienced ourselves during our visit to Malawi. The Zomba Central 
Hospital always seemed to operate at above maximum capacity, and there was a significant 
proportion of foreign health care personnel working throughout Malawi, especially at the bigger 
hospitals at the regional level. 
The presence of foreign health care professionals may also raises issues on its own. We got the 
impression that many of the foreign doctors who travel to Malawi to work were young and 
inexperienced, and had little to no experience with the tropical diseases, the chronic illnesses and 
lack of resources that characterize the clinical landscape in Malawi. We talked to a few foreign 
doctors working at the Queen Elizabeth’s Central Hospital in Blantyre, who felt that their knowledge 
was inadequate for the amount of responsibility they had been given, and that they themselves did 
not get as much out of it as they had hoped.  
Additionally, most of the foreign health care personnel we talked with described short temporary 
employment periods, typically from three to six months at a time, as common among foreign health 
care personnel in Malawi. If this correlates to reality, the expertise the foreign doctors bring with 
them may lack continuity and feel fragmented and disorganized. The constant need for training the 
newly arrived foreign doctors may put an additional strain on the available resources, and only has a 
temporary benefit. These factors may in turn affect the general quality of health care, as well as the 
management of various diseases in Malawi, including malaria.  
If the foreign health care personnel worked for a longer time in Malawi, the country would probably 
need to use fewer resources on the training of these temporary workers. In this way, the country 
may see financial benefits, while at the same time freeing up human resources in the health care 
system so that other workers can focus on patients, not on the training of new, foreign and 
temporary doctors. Additionally, the quality of the health care expertise the foreign workers provide 
would probably be greater because they would gain additional knowledge through experience with 
the clinical landscape in Malawi. At the same time, this will probably impede the recruitment of 
foreign workers to Malawi. 
6.1.2 The quality of the health care workers 
Another challenge facing Malawi is the quality of the health care workers themselves. For instance, 
WHO recommends that microscopy should be used in the diagnosis of malaria. However, in order to 
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utilize diagnostic microscopy, several costly requirements have to be fulfilled in order to avoid a 
potential increase in error, which may lead to misdiagnosis and mistreatment (3). 
During our stay in Malawi, we got the impression that almost all of the health care professionals 
were very diligent and hard working. At the same time, we observed one instance where equipment 
was used incorrectly during our visit to the health care institutions; this did not seem to be a result of 
negligence, but rather a failure in proper training of the health care professional using the 
equipment. It is worth noting that this probably was an isolated incident; however, the potential 
ramifications of systematic errors in the handling of equipment may be severe, and this incident 
serves to emphasize the importance of proper training. 
6.1.3 The challenges in diagnosing malaria 
According to WHO, potential malaria patients of all ages should receive diagnostic tests in Malawi; 
however, if diagnostic equipment is lacking, treatment on basis of clinical suspicion is indicated. Not 
confirming the diagnosis will probably lead to overtreatment (3), but at the same time patients with 
malaria will get the treatment they need before it is too late (123). Another concern is that 
overtreatment will increase antimalarial resistance development (41). The question quickly becomes 
whether it is cheaper to implement parasitological confirmation rather than over-treating the 
population and in the process risk development of antimalarial resistance. 
The WHO guidelines stipulate that the malaria diagnosis should be confirmed through microscopy; 
failing that, RDTs should be utilized (3). As mentioned above, using diagnostic microscopy requires 
implementing several costly measures (3), making it unrealistic to implement in anything but the 
larger health care institutions in Malawi (1). 
Using RDTs also requires additional elements before they can be implemented. This includes 
knowledge of the epidemiology in the relevant areas, as parasite densities and therefore the optimal 
type of RDT will vary with this parameter (3). Selecting an RDT with low sensitivity may work well in 
an area with high disease transmission, while the same RDT in an area with low disease transmission 
will probably underdiagnose the disease. In addition to the considerable epidemiological groundwork 
needed before starting using RDTs (3), the epidemiology of malaria will likely vary over time, 
requiring repeated assessments at regular intervals. This is another considerable challenge in a 
country such as Malawi, where resources are already spread thin. 
However, the potential benefits of confirming the malaria diagnosis are significant and probably cost-
effective; the reduction of unnecessary treatments will have significant economic benefits, as well as 
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lowering the risk of developing resistance and missing other diseases causing fever (2). Malawi 
started using RDTs in 2011 (1). 
6.1.4 Selecting the right treatment 
Malawi follows the WHO guidelines when it comes to malaria treatment. For uncomplicated malaria, 
the first-line treatment in Malawi is artemether–lumefantrine, and the second-line treatment is 
artesunate–amodiaquine; both drugs are ACTs and recommended by the WHO. For complicated 
malaria, Malawi still uses quinine (1). However, as discussed earlier, recent research indicates that 
using artesunate monotherapy may be a better choice for treating complicated malaria, and Malawi 
and many other countries may benefit from changing the first-line treatment for complicated malaria 
to artesunate; this is reflected in the latest malaria treatment guidelines from WHO (2). 
There are several challenges involved in treating malaria in Malawi, one of the biggest being drug 
shortages (139). In order to treat malaria effectively, it is vital that health care personnel have access 
to the first- or second-line drugs. Recent efforts in Malawi have focused on strengthening the drug 
supply chain and frequently assessing the current drug stockpiles (1). 
In addition, the national treatment guidelines stipulate that malaria should ideally be treated within 
24 hours of symptom debut (140); this proves to be an additional challenge for several reasons. First, 
while much of the population recognize that fever can be caused by malaria, far from everyone will 
visit a doctor for help (139). Secondly, even if they do want to visit a doctor, a significant proportion 
of Malawi’s population lives in rural areas with limited transport capabilities (134), discussed later, 
making it almost impossible to reach treatment before 24 hours has elapsed. 
Chloroquine was readily available for purchase over-the-counter at all the major pharmacies we 
visited in Malawi. A treatment course of chloroquine was significantly cheaper than a treatment 
course with the current first-line treatment in Malawi. This represents a possible issue in the future. 
If the general population prefer using the cheaper chloroquine to the more expensive first-line 
treatment for self-treating malaria, ignoring the government’s recommendations in the process, part 
of the rationale for using ACTs is lost. Malaria parasites in Malawi are among the most chloroquine 
sensitive in the world, but if a selective evolutionary pressure is applied to the parasites, it is likely 
that chloroquine resistance will develop rapidly, considering the extent of chloroquine resistance in 
the neighbouring areas (46). An important way of counteracting this is the recommendation that 
first-line treatment should be given free of charge at health care institutions (140). 
At the same time, as discussed earlier, because only about 10% of the suspected malaria cases are 
confirmed through parasitological diagnosis, there is probably a significant overtreatment with ACTs 
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in Malawi (139). Because of the limited diagnostic capacity, clinicians and health care personnel are 
often left to make a diagnosis based on clinical symptoms alone; some febrile patients without 
malaria will probably receive antimalarial treatment because of this. In addition to the fact that the 
real cause of the fever goes untreated, overtreatment increases the risk of resistance development. 
This is perhaps especially true for the non-artemisinin partner drugs in the ACTs, which have a long 
half-life, meaning that malaria parasites may be exposed to sub-therapeutic drug levels in the time 
after the treatment (46). 
Even patients where parasitological confirmation has been performed may end up treated for 
malaria when they are not malaria sick. Part of this comes from the method, which may be too 
sensitive for the area and therefore pick up false positives, but this may also be due to health care 
professionals distrusting the diagnostic test results, especially if they are negative (139). 
These problems underscore the importance of integrating sensitive and selective parasitological 
confirmation with coordinated drug use. A coordinated effort to educate the health care 
professionals responsible for treatment may help alleviate some of the potential problems down the 
line. 
6.1.5 Preventing malaria in Malawi 
There has been a big focus on distributing ITNs throughout Malawi, and 60% of households now have 
at least one ITN. Even if the goal of 80% has not been achieved, the improvement from the 6% 
ownership in 2002 is substantial (139). As the current national guidelines recommend that everyone 
in malaria endemic areas use bed nets, the remaining distance to full coverage is still considerable 
(1). In the households with bed nets, the youngest children should be prioritized (3, 140).  
ITNs were provided free of charge for pregnant women who made a visit to an ANC clinic and to 
children at their first visit to a vaccination clinic. The nets distributed through health clinics and 
campaigns are LLINs, which last longer than regular insecticide-treated nets (1). The effect of the 
insecticide decreases with time, and the deterioration rates varies between different areas. WHO 
therefore recommends evaluating the net efficacy in areas of large campaigns to estimate how soon 
a new campaign should be executed (65). This will give useful information for planning campaigns, 
but the research demands resources. If the duration of nets seems to be short, information of net 
maintenance may be useful (3). In addition, distribution to children after infancy may be 
implemented as a way to increase utilization among the older preschool children (140). 
The LLINs are given freely through health clinics to high-risk groups, while others purchase their nets 
in commercial outlets (1). The ownership of nets among the rest of the population therefore relies on 
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them prioritizing this purchase. According to locals we talked to during our visit in Malawi, a big ITN 
(covering a bed for two people) cost around 2000 kwacha, which at the time was equivalent to about 
US $5. He described this as an investment he saved up money for, implying the need of prioritizing 
this in his personal budget. The commercial distribution may result in increased socio-economic 
association regarding ITN ownership, increasing the burden among the poor. However, there are also 
positive sides to this distribution method. The commercial nets need less subsidization and the 
method is therefore more sustainable. The money that would have been used on subsidizing nets to 
non-pregnant adults may therefore be used on nets for the high risk groups instead. 
The efficacy of bed nets also depends on the correct utilization of the available nets. As mentioned 
earlier, several surveys from different sub-Saharan countries have seen that utilization of bed nets is 
not carried out in all households with an available net (72, 74, 75). Several factors were correlated 
with the use, including education of the parents and their knowledge about malaria transmission. 
Educating the public in using the nets correctly, how malaria is transmitted, and the possible benefits 
from protecting oneself from mosquito bites, could help improve the utilization of nets (72, 75, 79). 
As the risk of transmission is highest after dark, methods for protecting oneself outside of the bed 
net might also be beneficial. 
IRS is another potentially effective method of controlling malaria in Malawi; it was very recently was 
expanded from one to seven districts in Malawi (1). The recommendations from WHO when it comes 
to using IRS are clear. IRS is usually the first-line intervention in areas with a high rate of seasonal 
transmission, and it is a good tool to rapidly decrease the amount of transmission. However, if the 
results are to be maintained, several years of continuous spraying have to be done (81). 
While bed nets are a largely one-time expense with infrequent additional costs, given that they are 
reusable and long lasting, usage of IRS requires a long time commitment and follow-up (80). This 
makes it a more extensive form of intervention, and also affects its cost effectiveness. Introducing 
and continuously using IRS requires frequent monitoring of the situation at hand (80), which makes it 
a potentially very costly public policy to implement. On the other hand, bed nets require a personal 
commitment from the person at risk (74, 75), while IRS should be done by independent professionals 
(80). This means that IRS may be less dependent on many of the external factors that affect the 
usage of bed nets, including information and education of the public. It is possible that educating a 
skilled spray team capable of covering large parts of the population is more cost effective and easier 
than educating an entire community in the usage of bed nets. 
One additional complicating factor is the requirement of a multi-disciplinary team when it comes to 
using IRS, because of the extensive pre-emptive research needed before the implementation of this 
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method. In addition to the qualified medical personnel required to assess the malaria situation, many 
other factors are also relevant to the usage of IRS, including entomological and societal factors, and 
should be assessed by respective qualified personnel (81). 
Additionally, one of the big challenges in relation to preventive measures is the general lack of 
information, especially on the cost effectiveness of both ITNs and IRS, the effectiveness of combining 
the two, and which of the two selects most strongly for insecticide resistance. Even though there is 
little solid information on the present alternatives for preventive treatments, the need for 
developing novel and effective insecticides is pressing (82). 
There is a lot of uncertainty about the long-term effects of both utilizing current preventive measures 
as well as researching future options. The potential reward, with reduced or even eliminated malaria 
transmission, is huge, but the associated costs are high as well, and with no guarantees of any pay 
off. This short term vs. long-term dilemma permeates the entire malaria discussion, but especially 
when it comes to preventive measures; using IRS for a long time will probably reduce transmission, 
but at high cost (81). With today’s knowledge, this makes it very difficult to know what priority 
preventive measures should have, but with more research, these questions may be easier to answer. 
Another important discussion is the usage of pyrethroid-based IRS in areas with pyrethroid based 
ITNs. It is highly probable that the short-term effects of using a pyrethroid-based IRS in an area with a 
high malaria transmission rate will have a favourable effect on the prevalence of the disease; 
however, long term effects include a high possibility of the vector developing insecticide resistance. 
This would mean a reduced efficacy of both the pyrethroid IRS and ITNs, which would potentially be 
much more costly in the end (82). 
IPTp was first implemented in Malawi’s national guidelines for managing malaria in 1993. In a survey 
from Malawi from 2012, 54% said they had taken the recommended course of IPTp during their last 
pregnancy, while 76% had taken at least one dose of IPTp. This means that a significant proportion of 
pregnant women only receive one round of IPTp, or even no IPTp at all (1), raising concerns about 
the efficacy of the measure. Several trials have compared the efficacy of IPTp given with different 
frequencies, but these show inconsistent results. The general tendency implies that pregnant women 
receiving two or more doses of SP show better effect (91, 130, 131).  
The importance of increased frequency of IPTp is highest in HIV-infected pregnant women (131). 
After trials demonstrated a significant increase in effectiveness of IPTp in HIV-infected pregnant 
women when the frequency of administration increased, WHO started recommending three doses to 
HIV-infected pregnant women (34). In Malawi, over 10% of adults are HIV positive (134). In view of 
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their benefit from more frequent IPTp, this high prevalence shows the importance of following the 
recommended regimen of at least two doses of SP. 
IPTp is given routinely at ANC visits, which 90% of women in Malawi attend at least once during their 
pregnancy. As theorized earlier, the low coverage of IPT compared to attendance at ANC clinics may 
be a result of several factors, among them imprecise guidelines on when the IPT doses should be 
given, shortages of equipment or the drug itself, as well as concerns about the safety and efficacy of 
the drug (1). 
The confidence in SP’s efficacy may be declining as a result of the increased resistance towards SP 
and the consequent replacement of SP as the first-line drug in Malawi. However, high treatment 
failure rates in children does not necessarily imply a similar failure rate of IPTp. The effect of two 
doses of SP to HIV-negative pregnant women was still significant compared to those not receiving 
IPTp in settings with relatively widespread SP resistance (131). This implies that there still is a use for 
IPTp with SP when used according to guidelines in Malawi, where resistance to SP is widespread. 
6.1.6 Resistance development in Malawi 
Another challenge facing Malawi and other malaria endemic countries is the development of 
resistance, both to antimalarial drugs and insecticides (63). 
Performing research to assess resistance is one of the central elements in the WHO guidelines. As 
said earlier, WHO requires that resistance assessed regularly when using methods that may induce 
resistance. The reason for this is clear: The cost, both economic and for the public health, is 
unacceptable if resistant disease vectors or parasites should develop (46, 82). 
This quickly becomes apparent when looking back at the history of malaria treatment, which has 
largely been shaped by continuously developing resistance. Following the increased parasite 
resistance to chloroquine in the late 20th Century, the world saw an increase in malaria cases despite 
increased funding on malaria control, with devastating consequences. Great strides have to be taken 
in order to contain and prevent the development of new resistance, so that a similar situation may 
be avoided in the future (46). 
Malawi follows the WHO recommended guidelines when it comes to monitoring antimalarial 
resistance. These state that resistance towards first- and second-line treatments should be assessed 
every other year (46). During our stay in Malawi, the Ministry of Health were in the process of 
assessing the efficacy of the first-line drug (AL) in addition to the second-line drug (AA), as well as a 
third ACT, DP. 
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6.1.7 Inequality of wealth and the burden of disease in Malawi 
The enormous inequality of wealth and access to health care is another problem in Malawi. As 
mentioned earlier, Malawi is a poor country with limited available resources, and the resources 
should be utilized where they will benefit the largest amount of people. This means that larger 
settlements, mainly the larger cities, have traditionally been prioritized with access to adequate care 
through diagnosing and treating of malaria (1).  
Malaria is by its nature a disease that mainly burdens the poor. As we have seen throughout this 
paper, malaria is a disease that is preventable, and it is readily treatable, given the access to certain 
resources. Poverty increases the risk of both getting malaria and dying of malaria (63).  
In addition, transportation costs are also very high in Malawi, with gasoline prices at 710 kwacha, 
which at the time of the visit equalled US $1.8, per litre; this price was expected to rise in the near 
future. This severely limits the poor population’s ability to travel, since both cost of private and 
public transportation is dependent on the gasoline price. Thus, getting to a health care institution 
capable of treating malaria may represent a major financial challenge for a large proportion of the 
poor population. 
Closely related to poverty is the lack of knowledge about malaria in Malawi’s general population. 
Malaria treatment and prevention services are challenged by community attitudes such as late 
treatment seeking behaviour, as well as misconceptions about IPT, ITNs and treatment. This is 
particularly a problem among the poor. Even though the guidelines themselves are clear about what 
needs to be done, fully implementing them requires cooperation from the population at risk. The 
population needs to be educated on protecting themselves against mosquitoes, recognizing malaria 
symptoms, as well as seeking treatment. As such, educating the people in correct adherence to the 
guidelines is necessary (1). 
Additionally, Malawi is a country with a lot of co-morbidity, especially with HIV. As noted earlier, the 
HIV prevalence in Malawi is high, over 10% nationwide (134). In areas where the malaria 
transmission is insufficient to develop immunity, HIV-infected have an increased risk of developing 
severe malaria (39). Preventing malaria in HIV-infected is a challenge in itself, especially among 
pregnant women. The current prevention guidelines in Malawi stipulate that SP should be used as 
IPTp (1). However, many HIV-positive pregnant women already take prophylactic co-trimoxazole 
against opportunistic infections. Co-trimoxazole contains sulfamethoxazole, a sulphonamide, and 
these patients should not use other drugs containing sulphonamides, for example SP (89). In practice, 
this problem can be solved by switching to another drug for IPTp; this will be discussed in detail later.  
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Another worrying aspect of the high HIV prevalence is the increased risk of being infected with HIV 
after receiving blood transfusions (37). Malaria is an important cause of anaemia in Malawi, and 
blood transfusions following severe anaemia may have devastating consequences if the patient 
becomes infected with HIV (37). 
There is a general lack of information and specific guidelines when it comes to co-morbidity of 
malaria and other diseases. It is unclear how much of a problem this is in practice, but given the large 
proportion of co-morbidity in several African countries due to the geographical overlap of several 
different diseases, this can be a valuable area to focus on in the future. 
Another potential obstacle is the rapidly growing population in Malawi. In addition to increasing the 
strain on an already strained public health care system, the population growth itself is 
disproportionate, with the poorest parts of the population increasing the most (134). This means that 
the population that is most at risk and the weakest equipped to fight the disease continues to grow, 
placing an additional burden on the health care system. 
Finally, external factors such as climate also affect the malaria situation in Malawi. Even though there 
is transmission throughout the year in most parts of Malawi, the incidence varies largely depending 
on the season, with transmission peaking in the wet seasons (1). This may complicate selecting the 
optimal prevention strategies and diagnostic capabilities, as well as making drug stockpiles difficult to 
plan.  
6.2 The implementation of the WHO guidelines in Malawi 
In this part, we will discuss the international and national guidelines as they relate to Malawi. We will 
look at how these guidelines form the basis of malaria prevention, diagnosis and treatment in 
Malawi, as well as the challenges that Malawi is facing when it comes to implementing these 
measures. Finally, we want to discuss what the consequences of the degree of adherence to the 
different guidelines have, and if any of these ramifications are more serious than others are. 
6.2.1 The relevance of guidelines 
We feel that both the international and the national guidelines are reasonably clear and specific, and 
that they can lay the groundwork for effective measures against malaria. Developing these guidelines 
has been a long and costly process because of the research behind them, and the efforts continue to 
this day.  
At the same time, some of the recommendations outlined in the guidelines are more difficult to 
implement for several reasons. Still, having specific guidelines will help immensely in figuring out 
how to systematically and consistently prevent and treat malaria. One of the best examples of how 
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guidelines can make the fight against malaria more effective comes from standardized treatment 
guidelines. Instead of having a myriad of different options to choose from, having a standardized 
treatment helps physicians and pharmacists to make good therapeutic decisions quickly. 
6.2.2 The applicability of international guidelines in Malawi  
Malawi has implemented most of the intervention methods recommended by WHO against malaria 
in holoendemic areas, with the significant exception of IPTi (1). International research on IPTi has 
demonstrated good effect during administration (93-95), and the rebound effect seems to be 
transient (28, 106). The recommended regimen is attached to the recommended vaccination 
programme, and would therefore utilize an already existing programme (3). Despite all these positive 
aspects of IPTi, the recommendation is still not implemented in the national guidelines (92). 
The main reason for this is probably the requirement of using molecular resistance markers. Before 
the recommendation can be implemented, the prevalence of a mutation for resistance in the 
parasite has to be assessed and confirmed to be under a certain threshold (3). This demands 
research on a molecular level, a very costly demand that may be difficult to fulfil. Resistance is often 
measured in treatment failure rates in the population, a parameter that seems more practical to 
evaluate and to interpret, instead of using molecular markers. If the guidelines where based on the 
treatment failure rate in children instead of the prevalence of a specific genetic marker, IPTi may be 
easier to implement for countries with limited resources (92). However, the high rates of treatment 
failure in Malawi mean that IPTi would probably not be implemented under the current 
circumstances. 
Other WHO guidelines not implemented in Malawi’s national guidelines are seasonal malarial 
chemoprevention and larviciding. Seasonal malarial chemoprevention is recommended in sub-
Sahelan areas with seasonal transmission (126). As most of Malawi has perennial transmission (139), 
interventions directed at reducing transmission all year are prioritized instead.  
Larviciding is recommended in urban areas with fixed breeding sites as an addition to the ideal use of 
IRS and/or ITNs. Malawi has recently started implementing IRS in the areas with the highest burdens 
of disease, and focusing on fully implementing this method should be prioritized first (85). As Malawi 
has transmission with An. gambiae (138), a vector without fixed breeding sites, mapping the 
breeding sites would be difficult (85). In addition, most of the population in Malawi lives in rural 
areas (134). In the current situation, larviciding is therefore not recommended in Malawi.  
All of the factors mentioned so far in the discussion, make fulfilling the WHO guidelines for malaria a 
difficult task in Malawi. The resources needed for adhering to some of the recommendations may be 
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utilized more effectively other places in the health care system, or for making sure that the 
recommendations that are utilized are followed more closely. In the end, as it usually is when it 
comes to public health care policies, it ends up being a question about prioritizing. 
6.2.3 Prioritizing the guidelines 
The WHO guidelines recommend detailed evaluation and research of the different interventions on a 
national or local level before, during and after implementation. They also specify which areas that 
will benefit most from the different interventions when it comes to transmission intensity, vector 
species and local resistance. As the resources needed to adhere fully to the guidelines may exceed 
the available resources, achieving certain guidelines may seem unachievable in many situations. 
Perhaps one solution is to try to assess which measures are the most cost-effective in particular 
conditions. Making recommendations for focus areas for specific countries or areas may be more 
effective and lead to a more coordinated effort, compared to leaving each country to decide for 
themselves what they want to focus on. In this way, it would become easier to implement the most 
important aspects of the guidelines even though the nation is unable to abide completely to all of the 
recommendations at the same time. 
This highlights one of the central challenges when it comes to guidelines: making guidelines that are 
specific enough to be useful, while at the same time being general enough to make room for the 
national differences between malaria endemic countries.  
6.2.4 Developing national guidelines 
With basis in the international guidelines from WHO, Malawi has formed their own national 
guidelines (1). Developing national guidelines is costly and requires a lot of effort, but we feel that 
having a set of national guidelines is an invaluable in the fight against malaria in a malaria endemic 
country. 
Part of the problem of international guidelines is that they often may be too generalized. Having own 
national guidelines with only a subset of the different alternatives given in the international 
guidelines may make it possible for health care professionals to work more efficiently, and it makes it 
easier to adjust for the specific challenges in one particular nation. National guidelines should ideally 
be a selection of the most relevant recommendations made in the international guidelines, made 
understandable by the health care professionals that use them. 
However, Malawi is still a country with a lot of diversity, both geographically and socially; perhaps 
Malawi could benefit from using even more specific regional guidelines in order to further intensify 
the fight against malaria. The current national guidelines do open for regional differences in the 
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implementation of different preventive treatments (e.g. IRS, which previously only was used in the 
Nkhotakota district (1)), but having specific guidelines tailored to the local conditions may serve to 
further increase the effectiveness of different measures. 
It quickly becomes a question of diminishing returns. Having international guidelines is an essential 
tool in the fight against malaria; national guidelines may aid this even further by making it easier to 
make decisions correct for that particular country. Regional guidelines will probably not hurt the 
cause, but the cost-benefit of such regional guidelines is probably dubious at best, when so much of 
the same effect can be achieved by slightly more general national guidelines.  
Another benefit of having national guidelines instead of following international guidelines is that the 
national guidelines can have a faster turnaround than the international ones. The international 
guidelines is a comprehensive work, and changing them is not done overnight. As such, national 
guidelines give the health care system in a country a better response time to new information. As will 
be discussed later, parts of the national guidelines in Malawi have frequently been ahead of the 
curve when it comes to preventing and treating malaria.  
6.2.5 Partial implementations of guidelines 
Another question worth discussing is whether implementing the guidelines optimally is a 
requirement for implementing them at all. WHO stipulate several requirements that have to be 
fulfilled in order to use specific measures. However, with the limited resources several of these 
countries have at hand, many countries will inevitably fail to fulfil these conditions. 
The informal 80–20 rule states that 20% effort gives 80% of the results. While this is not exactly a 
scientifically rigorous principle, we still feel that it rings true when it comes to this situation. It 
illustrates that doing a little goes a long way, but achieving optimal results require a whole lot more 
effort; it is another way of stating the law of diminishing returns. Based on this principle, and in light 
of the lack of alternatives, we feel that using the methods and measures described in the guidelines 
can be justified in some areas, even if the requirements stipulated by WHO are not fulfilled, when 
considering the alternatives. 
One good example to illustrate this point is the requirements placed on confirming the malaria 
diagnosis. In order to utilize microscopy or RDTs, as previously discussed, several requirements must 
be fulfilled. At the same time, even failing at fulfilling these criteria, the margins of error will probably 
be magnitudes less than making a clinical diagnosis. 
Another example is treatment. We observed over-the-counter sale of chloroquine. Using chloroquine 
against malaria is not compatible with the current treatment guidelines, even though the malaria 
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parasites in Malawi are reasonably sensitive to chloroquine. However, the free sale of chloroquine, 
which is significantly cheaper than the current first-line treatment in Malawi, may result in better 
treatment coverage for people that for some reason cannot utilize the first-line treatment provided 
for free by the government. 
The same applies to preventive measures, which will have at least some effect even if the 
corresponding requirements are not fully met. For example, as mentioned earlier, non-insecticide-
treated nets will still give some protection, even if this effect is low compared to ITNs; if the 
alternative to using non-insecticide-treated nets is using no nets at all, using the nets will end up 
saving lives, even if they are not used to their full potential (64). The same principle goes for other 
measures as well. Even if IRS is performed incorrectly and for instance does not cover 100% of the 
surfaces, the effect will most likely be higher than without the intervention. 
6.2.6 Guidelines requiring strict adherence 
Even if some of the requirements surrounding the malaria guidelines can probably be eased without 
major consequence, there are some guidelines that probably call for stricter adherence to the 
requirements.  
One example of this is the problem concerning resistance. Resistance to both antimalarials and 
insecticides have shaped the fight against malaria for several decades, and has led to vast financial 
and human costs. In order to contain and even counteract the development and spread of resistance, 
it is important that the guidelines are followed as strictly as possible (46). 
To use one of the previous examples, the sale of over-the-counter chloroquine in pharmacies in 
Malawi can represent a potential problem. Even though chloroquine is not used in the treatment of 
malaria, there is currently a lot of on-going research on the use of azithromycin–chloroquine in 
intermittent preventive treatment, especially in pregnant women (36). If chloroquine becomes 
widely used in the population, both because of its availability and cost, and resistance develops as a 
result, the consequences may be an increased burden of disease among pregnant women.  
Ethically, the correct usage of IRS should be prioritized as well; in particular, avoiding unnecessary 
exposure to dangerous substances should be kept to a minimum. Training staff in correct and safe 
insecticide spraying is essential in order to keep the workers safe (81). 
Overall, we feel that most of the guidelines are strict for a reason, and that even though many of the 
requirements stipulated by WHO may seem costly, they may end up with a lower economic and 
health cost in the future. For instance, researching the efficacy of the treatments regularly will make 
sure that treatment failures are kept to a minimum; assessing the malaria prevalence in an area may 
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lead to choosing the correct diagnostic tool, preventing overtreatment and potentially development 
of resistance.  
6.3 Malaria research in Malawi 
In this chapter, we will take a look at the specific challenges regarding the current research projects 
we were in contact with in Malawi, in addition to how these research projects may impact Malawi’s 
public health policies in the future. Finally, we will assess the importance of local research, and how 
local research may end up influencing international guidelines. 
6.3.1 Research challenges 
Research is both costly and time consuming. One of the big problems of research is staying relevant; 
when research projects span years, by the time they are finished and the results are published, they 
may lack much of their original relevance. In addition to this, we saw several challenges surrounding 
the research projects described earlier in this document.  
One of the central challenges when it comes to researching in Malawi is the literacy level. A 
significant portion of the population in Malawi cannot read which leads to several problems when it 
comes to research. The most significant of these problems is giving consent. In Malawi, consent 
forms are given in both English and the local language, Chichewa, but if a participant is illiterate, an 
impartial witness has to validate that the verbal explanation is the same as the written. In order to 
ensure that the participants have a good understanding when it comes to the study, they are asked 
questions about the study; failing to answer these questions restarts this process, and the 
information has to be repeated in order to guarantee informed consent. 
If the participant is a minor, their legal guardian is informed for them and has to make a decision; the 
same rules apply to legal guardians as with the other participants. 
An additional challenge when it comes to recruitment is the superstitious beliefs in the population, 
especially among the poor and in the more isolated villages. In order to overcome this challenge, 
strategic cooperation with the community leaders was sometimes necessary. 
Related to this, the general lack of knowledge about health and health care is also an obstacle. The 
Pfizer sub study assessing the effect of IPTp in asymptomatic pregnant women with parasitaemia has 
some trouble with recruiting women to the project, simply because the women feel fine and do not 
feel the need to take medication. Some of the projects may also go against common sense, e.g. 
drawing blood from anaemic children in the MALARID study; however, this is necessary in order to 
do the research needed to change public policies down the line. This further illustrates the need for 
public awareness campaigns. 
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Finally, the logistics presented another problem in itself. The participants had difficulties getting to 
the research centres in question. Many of the study participants came from rural areas with poor 
road conditions and a general lack of transportation facilities; in addition, they were often very poor, 
and could not afford the bus ticket to get to the research site. This problem was solved partly by 
reimbursing the travelling costs, which were given on either arrival, or, more rarely, up-front. Up-
front payments were problematic as, as one researcher explained, they ran the risk of losing both the 
transportation money and the follow up for that participant. Another solution was to do home visits 
to the participants instead of requiring them to show up to the research site itself. This was a good 
method for ensuring a better follow-up rate, however it also presented with some problems on its 
own; participants were frequently not at home, prompting the researchers to have to go back on the 
following day.  
6.3.2 The role of research on changing public health care policies 
As we have seen, research is expensive, time consuming and technically challenging, but at the same 
time, research provides invaluable information that can be used to change public health care policies 
in meaningful ways.  
6.3.2.1 Resistance surveillance 
As mentioned earlier, resistance against antimalarial drugs and pesticides is an important challenge 
in the fight against malaria. Research on drug resistance has changed Malawi’s national guidelines for 
malaria treatment twice: first in 1993 because of the increasing chloroquine resistance, and second 
in 2007 because of SP resistance (1). Continued monitoring of resistance towards the new first line 
drug, ACT, may help implement a rapid policy change if resistance develops. 
6.3.2.2 Alternatives for IPTp 
As a further increase in SP resistance may jeopardize the efficacy of SP as IPTp, drugs for replacing SP 
are being sought. The coverage of IPTp may also be reduced by the use of co-tromoxazole in HIV-
infected pregnant women, as this combination increase the risk of adverse effects (89). As the 
prevalence of HIV is high in Malawi (138), this may add to the need of finding an alternative drug for 
IPTp. Two of the on-going studies we observed in Zomba assessed azithromycin–chloroquine as an 
alternative for IPTp, in hope that this drug combination will demonstrate a higher efficacy than SP. If 
the usefulness exceeds the increased side effects at administration, this could give more effective 
malaria prophylaxis (36).  
Azithromycin is an antibiotic drug and thereby also reduces the prevalence of sexually transmitted 
diseases and pneumonia. Again, the importance of monitoring the possible development of 
resistance is important, in both parasites and bacteria (36). If the trials show promising results, this 
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may help control and even revert the increasing SP resistance in Malawi, as IPTp is the last indication 
for SP administration in Malawi. Research on an alternative for IPTi would also be useful, as 
resistance towards SP may be the main reason for not implementing this preventive method into 
national guidelines (92). 
6.3.2.3 Iron supplementation 
The MALARID study is another example on how ingoing research may affect the national guidelines. 
Malaria is associated with anaemia, and moderate and severe anaemia is common on presentation 
among symptomatic malaria infection in children. One of the mechanisms by which malaria can 
induce anaemia is erythropoiesis. As mentioned earlier needs all aetiological components to be 
addressed to reverse this suppression, including iron deficiency. Iron supplementation may therefore 
increase erythropoiesis in children with malarial anaemia (61). 
The MALARID study hopes to assess whether iron supplementation should be given routinely to 
anaemic children and when this supplementation would be of best use. Their result may thereafter 
be incorporated into national policy on how to address this problem. At the moment, insecurity 
regarding both the safety and effectiveness of iron supplementation may reduce administration of 
iron to moderate anaemic children, though there appears to be little evidence to substantiate this 
view (61). As anaemia is common in Malawi (134), standardized guidelines for iron supplementation 
may increase utilization of this measure, and perhaps reduce the prevalence of chronic anaemia in 
the population. 
6.3.2.4 The role of local research 
National research assessing the insecticide resistance may inform the authorities to change their 
recommendations regarding IRS and bed nets. Implementing several of the preventive measures 
described in the guidelines requires assessment in order to select the correct course of action. Thus, 
local research has real significance when it comes to making sure that the selected measures are 
effective. 
One area of special attention when it comes to research in Malawi was the role of iron in malaria. At 
the time of our visit, the guidelines made no mention of post-treatment iron replacement therapy, 
but it was known that a substantial subset of patients had malaria-induced anaemia after treatment. 
Because of the lack of clear guidelines, iron treatment was given sporadically and inconsistently, 
without really knowing if it helped or harmed the patient. The research being done at the time of our 
visit may help in developing evidence-based guidelines for this aspect in the future. 
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6.3.2.5 The importance of local research and its relevance for international guidelines 
Local research showing reduced treatment efficacy or widespread side effects may lead to a rapid 
international response to change current guidelines. Since resistance develops locally, it is important 
that all malaria endemic countries perform research and regularly assesses the resistance situation, 
not only for their own sake, but also for the international antimalarial movement (46).  
The WHO guidelines are based on research done in malaria endemic countries, often performed by 
local authorities and health care professionals. The continued focus on local research makes sure 
that the guidelines are up-to-date and equipped to handle the ever-changing clinical landscape. 
6.4 The future role of DDT 
DDT made a huge revolution in the fight against malaria during and after World War II. Many 
countries in the western part of the world used DDT before a thorough investigation about the 
consequences of such use was assessed, and an uncritical attitude towards the pesticide caused an 
extensive and massive use of DDT in many different applications. After a while, however, the use of 
DDT was followed by an increasing scepticism, and research was performed to evaluate what 
potential hazards were involved with the use of DDT. This led to developing the current restrictions 
that limit the use of DDT today (4). 
In this part, we will discuss the consequences of the sceptical attitude towards DDT, and what the 
following ban for most uses of DDT means for the world. We will look at why it can be difficult for 
some countries to use DDT today, in part because of international attitudes and pressures. In 
addition, we have discussed what kinds of restrictions we think are necessary when it comes to the 
use of DDT, and what may perhaps be done in the future to change the current worldwide attitudes 
towards DDT. 
During the past years, there has been an extensive debate about how the positive effects of DDT 
have largely been neglected. The big focus on the uncontrolled and ignorant application of DDT may 
have drawn the attention from the fact that the use of DDT has achieved many goals that would 
otherwise not be achieved. It is easy to look back and decide the best course of action in hindsight, 
but it is important to ask whether DDT would have been used less if the potential harm was known 
beforehand. Many of the results in the fight against disease-bearing insects were achieved before an 
assessment of the potential human health risks was even possible; in the beginning, there was no 
real dilemma in the use of DDT, because the cons were simply not known (4). 
In addition, it is possible that it became easier for the West to ban DDT because of potentially 
negative health effects, considering that they had already achieved many goals through its use. 
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Without taking into account the current situation in malaria endemic countries, a ban on DDT might 
make sense; however, considering the heavy burden of malaria in large parts of the world, it is 
entirely possible that the potential benefits greatly outweigh the risks. However, the West shares its 
knowledge about the risks involved with the use of DDT in good faith, without, perhaps, fully 
realizing the pressing need for solutions that many malaria endemic countries so desperately need. 
For industrialized countries, the potential harm involved in the use of DDT may seem so severe that 
its use should be banned outright, even though its benefits may counterbalance the risks in other 
areas. 
Another challenge is that researching increasingly demands thorough precursory investigation, and 
extensive evaluations of the results before a conclusion can be reached. Criticism is an important 
part of research, and meeting new methods and products with scepticism is natural in today’s 
scientific landscape, for better or for worse. In order to approve of a new product, vast resources 
have to be used first to assess and reassess all aspects. For the developing world, particularly in 
comparison with the industrial world, there is a pressing need for solutions, and the need to evaluate 
all aspects of a new product or measure constantly, may compromise the economy of the country, as 
well as the quality of life and the ability to fight the disease effectively in a reasonably timely matter. 
In the end, it is not likely that this problem will be solved, as it is intrinsic to the ethical values of our 
society today; in order to do no harm, one first has to assess the benefits and risks involved, and that 
can be a costly and time-consuming affair. 
In the WHO guidelines for DDT, statistically significant investigations that confirm the harm DDT has 
on human health are rejected. Instead, the aspect of DDT that causes most concern is the increasing 
resistance, which is currently the limiting factor of its use. In addition, WHO mentions that there is a 
need for further investigation on potential harmful effects of DDT on humans, as there is no clear 
answer to this question today (132).  
WHO concludes that there still is a role for DDT in the fight against malaria, but that there is a need 
for developing new and effective insecticides (132). The scepticism and following ban of DDT in the 
industrialized nations has probably affected Africa’s opportunity to be able to make use of DDT. 
Because many countries in Africa, including Malawi, depend on the support and contributions from 
industrialized countries in the fight against malaria, the industrialized countries also have a lot of 
impact on decision-making. This may lead to several challenges. It may be difficult for industrialized 
countries to understand the plight of developing countries when it comes to malaria, and perhaps 
especially when it comes to time as a critical factor. Malaria is a preventable, treatable disease, and 
not being able to come to a consensus about which measures that can be used is probably one of the 
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reasons why malaria is still a problem in large parts of the world.  
Since DDT was banned in the USA in 1972, there has been little development of new and effective 
insecticides (82), especially when compared to the pharmaceutical industry, which has made huge 
progress in developing new medicines over the last decades (2). Is this a question about priorities, or 
is it a result of other factors? For a profit-driven industry, the priority is to develop novel solutions 
that are economically sound. Uncertainty about the long-term profitability of developing new 
insecticides may be one of the reasons why this development has been slow (4). 
DDT has achieved wonders when it comes to fighting insect-borne diseases in large parts of the 
world, but concerns about the potential harmful effects has led to limitations in today’s use. As a 
result, countries in Africa have not had the full opportunity to exploit the potential of DDT in the fight 




Throughout this paper, we have described the status regarding malaria in Malawi and which 
interventions are used to combat this problem, as well as how research may affect national and 
international guidelines. We have seen that Malawi has taken great strides in the fight against 
malaria over the last years; Malawi has achieved a lot with limited resources, and the general 
situation is improving. 
Malawi faces several difficult challenges when it comes to malaria. Malawi lacks the monetary and 
human resources to achieve satisfactory coverage of health care for the whole population. In 
addition, many challenges are related to the inequality of wealth in Malawi. Some of these 
challenges are difficult to overcome in the current situation in Malawi without significant 
socioeconomic progress and social restructuring. 
The current guidelines in use, both internationally and nationally, give Malawi a good set of tools in 
order to fight malaria. Even though Malawi has not been able to fully implement all aspects of the 
international guidelines, the measures they have implemented have had positive effects on the 
public health in Malawi, and have proven to be vital tools in reducing the burden of disease. 
Continued adherence to the guidelines is vital to achieving future success in the fight against malaria.  
Of all the challenges that are mentioned, we feel that spreading information and knowledge about 
malaria is among the most important. Making the population at risk more aware of the risks, 
preventive measures and treatment is probably a cost-effective way to promote increased adherence 
to the current guidelines. 
Nevertheless, the current lack of information makes it difficult to point the finger at any one thing 
that can be done better. We feel that the general lack of resources, both economic and human, in 
the Malawian health care system is the limiting factor in this situation. With resources spread so thin 
already, it is not easy to say where the priority in the future should be. Continuing to research and 
assess the current situation may reveal areas worth focusing on in the future, and that this may help 
Malawi in achieving a sustainable and effective long-term plan in fighting malaria. Over time, this 
may be more effective than focusing more effort on the performance of current guidelines. 
Furthermore, research is needed in order to ensure that the current measures are as effective as 
possible, and that novel ways of combating malaria may be developed. Solid research forms the 
backbone of public health policies, both on a national and international level; in order to change 
them in meaningful ways, sufficient research has to be performed first.  
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DDT has earlier had good results in the fight against malaria, but the potential hazards have given 
rise to scepticism. WHO has not been able to come to any conclusions about the health hazards 
associated with its use, but focuses on resistance as the main problem when it comes to DDT. This is 
a result of lack of knowledge, since the long-term effects of DDT exposure are uncertain. The 
implementation of DDT in recommendations may be justified, although it demands thorough 
evaluating beforehand and surveillance of any possible hazards, as well as monitoring resistance, 
during and after implementation. DDT should not be seen as a permanent solution, and ideally, 
research would find a new insecticide to replace DDT, but progress over the last few decades has 
been slow. 
Additionally, the fight against malaria in Malawi is largely dependent on several external factors. 
These factors include monetary support from other countries, as well as continued research by the 
pharmaceutical and chemical industry to find new and effective ways of treating and preventing 
malaria. Despite the challenges involved, the fight against malaria seems to be going reasonably well 
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